register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT05521984 | [
{
"id_field": "org_study_id",
"id_value": [
"202210013"
]
}
] | https://clinicaltrials.gov/study/NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. T... | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | [
{
"description": "Commercially available",
"name": "Dapagliflozin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Standard of care",
"name": "Carmustine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
... | [
{
"design_group_description": "* Dapagliflozin will be initiated by mouth once daily at the same time as standard of care chemotherapy (carmustine).<br/>* Dapagliflozin 5 mg by mouth once daily on days 1-84 (duration of study)<br/>* All patients will stop taking dapagliflozin after 12 weeks of treatment.",
... | [
"Pediatric Brain Tumor",
"Pediatric Solid Tumor"
] | [
"Washington University School of Medicine"
] | [
"Childrens Discovery Institute"
] | [
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "卡莫司汀",
"lang": "CN"
},
{
"name": "Carmustine",
"lang": "EN"
},
{
... | null |
NCT01011010 | [
{
"id_field": "org_study_id",
"id_value": [
"LCCC 0902"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA016086"
]
},
{
"id_domain": "PDQ number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"i... | https://clinicaltrials.gov/study/NCT01011010 | Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride and mitomycin, work in different ways to stop the growth of tumor cells, either by killing the ce... | Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC) | [
{
"description": "TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a \"pruned tree\" appearance on angiography. If a second TACE is to be performed it should be performed wit... | [
{
"design_group_description": "Single Arm Trial",
"design_group_title": "Single Arm",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease ... | [
"Liver Cancer"
] | [
"Lineberger Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "丝裂霉素",
"lang": "CN"
},
{
"name": "Mitomycin",
"lang": "EN"
},
{
"name": "マイトマイシンC",
"lang": "JP"
}
],
[
{
"name": "盐酸多柔比星",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride",
"lang": "EN"
},
... | null |
NCT05959707 | [
{
"id_field": "org_study_id",
"id_value": [
"HVTN 143/HPTN 109"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UM1AI068614"
]
},
{
"id_field": "acronym",
"id_value": [
"HVTN143"
]
}
] | https://clinicaltrials.gov/study/NCT05959707 | Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants | Part A:<br/>The purpose of this part is to study how the body's immune system reacts to a lab-made HIV-1 monoclonal antibody against HIV antigen when given in different doses. The study will also evaluate if the antibody is safe to give to people and does not make them too uncomfortable.<br/>Part B:<br/>The purpose of ... | A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies VRC01.23LS, PGT121.414.LS and PGDM1400LS Administered Via Intravenous Infusion in Adults Without HIV | [
{
"description": "VRC01.23LS will be administered IV over approximately 30 to 60 minutes.",
"name": "VRC01.23LS",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "PGT121.414.LS will be administered IV over approximately 30 to 60 minutes.",
... | [
{
"design_group_description": "VRC01.23LS 5 mg/kg to be administered via intravenous (IV) infusion at Month 0",
"design_group_title": "VRC01.23LS 5 mg/kg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"HIV Infections"
] | [
"HIV Vaccine Trials Network"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "PGT-121",
"lang": "EN"
}
],
[
{
"name": "PGDM-1400",
"lang": "EN"
}
],
[
{
"name": "VRCHIVMAB0115-00-AB",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "HVTN143"
}
] |
NCT03597282 | [
{
"id_field": "org_study_id",
"id_value": [
"NT-003"
]
}
] | https://clinicaltrials.gov/study/NCT03597282 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study inte... | An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma | [
{
"description": "Personal Cancer Vaccine",
"name": "NEO-PV-01",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "monoclonal antibody against PD-1",
"name": "Nivolumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_... | [
{
"design_group_description": "Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.",
"design_group_title": "NEO-PV-01 +... | [
"Metastatic Melanoma"
] | [
"BioNTech US, Inc."
] | [
"Apexigen America, Inc."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | null |
NCT04210752 | [
{
"id_field": "org_study_id",
"id_value": [
"EG-HZ-101"
]
}
] | https://clinicaltrials.gov/study/NCT04210752 | Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers | This is a Phase 1, first in human (FIH), randomised, active-controlled, double-blind study designed to assess the safety and tolerability and explore preliminary efficacy of the EG-HZ vaccine. Oversight will be provided by a Safety Review Committee (SRC). | A Phase 1, Randomised, Activator-Controlled, Double-Blind, Parallel Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers | [
{
"description": "Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)<br/>Route of Administration: IM injection",
"name": "Treatment 1 (EG-HZ-001)",
"... | [
{
"design_group_description": "Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)<br/>Route of administration: Intramuscular injection",
"design_group_ti... | [
"Prevention of Herpes Zoster (HZ)"
] | [
"EyeGene, Inc."
] | [
"Novotech (Australia) Pty Ltd."
] | [
[
{
"name": "Herpes zoster vaccine(EyeGene, Inc.)",
"lang": "EN"
}
]
] | null |
NCT00072410 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000339682"
]
},
{
"id_domain": "Memorial Sloan-Kettering Cancer Center",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MSKCC-03069"
]
},
{
"id_domain": "Ludwig Institute for Cancer Re... | https://clinicaltrials.gov/study/NCT00072410 | Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer | RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. Giving radiolabeled monoclonal antibody directly into the abdominal cavity may kill more tumor cells.<br/>PURPOSE: Phase I trial to study the effectiveness of givin... | Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized Monoclonal Antibody 3S193 (90Y-hu3S193) in Patients With Advanced Ovarian Cancer | [
{
"description": "Patients received a single dose of 10 mg of hu3S193 radiolabeled with the intended dose (mCi) of 90Y.",
"name": "90Y-hu3S193",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"humanized monoclonal antibody 3S193 radiolabeled with 90Y"
],
"type":... | [
{
"design_group_description": "Patients received a single intraperitoneal (IP) dose of 10 mg of hu3S193 radiolabeled with 10 millicuries (mCi) 90Y and 5mCi 111In-hu3S193 to enable imaging after dosing.",
"design_group_title": "Cohort 1",
"design_group_type": "Experimental",
"design_group_type_normal... | [
"Ovarian Cancer"
] | [
"Ludwig Institute for Cancer Research Ltd."
] | [
"National Cancer Institute"
] | [
[
{
"name": "Anti-Lewis Y monoclonal antibody(Ludwig Institute for Cancer Research)",
"lang": "EN"
}
]
] | null |
NCT05178693 | [
{
"id_field": "org_study_id",
"id_value": [
"RS - IC03"
]
},
{
"id_domain": "Imperial College London",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"21HH6544"
]
},
{
"id_field": "acronym",
"id_value": [
"LANTana"
]
}... | https://clinicaltrials.gov/study/NCT05178693 | Lutathera and ASTX727 in Neuroendocrine Tumours | Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to imag... | The Epigenetic Modification of Somatostatin Receptor-2 to Improve Therapeutic Outcome With Lutathera in Patients With Metastatic Neuroendocrine Tumours. | [
{
"description": "Cedazuridine 100mg + 35mg decitabine",
"name": "ASTX727",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Peptide receptor radionuclide therapy (PRRT)",
"name": "Lutathera",
"normalized_type": "c030b727164e46bf9a75d711c55b9... | [
{
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Peptide receptor radionuclide therapy (PRRT)",
"intervention_name": "Lutathera",
... | [
"Neuroendocrine Tumors"
] | [
"Imperial College London"
] | [
"Advanced Accelerator Applications SA"
] | [
[
{
"name": "地西他滨/西达尿苷",
"lang": "CN"
},
{
"name": "Decitabine/Cedazuridine",
"lang": "EN"
}
],
[
{
"name": "(177镥)镥氧奥曲肽",
"lang": "CN"
},
{
"name": "Lutetium Dotatate LU-177",
"lang": "EN"
},
{
"name": "ルテチウムオキソドトレオチド(177... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2a884ed0ea92224e5a2a582a404325ea",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "LANTana"
}
] |
NCT07053319 | [
{
"id_field": "org_study_id",
"id_value": [
"20230457HU-504077"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK024092"
]
},
{
"id_field": "secondary_id",
"id_value": [
"R01DK024092;20230457HU-504077"
]
... | https://clinicaltrials.gov/study/NCT07053319 | SGLT2i, Pioglitazone, and Ketone Production in T2D | To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects). | Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus | [
{
"description": "A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.",
"name": "Empagliflozin 25 MG plus Pioglitazone placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [... | [
{
"design_group_description": "Empagliflozin 25 mg/day plus pioglitazone placebo",
"design_group_title": "Empagliflozin plus Pioglitazone placebo",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"inter... | [
"Type 2 Diabetes"
] | [
"University of Texas Health Science Center At San Antonio"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "盐酸吡格列酮",
"lang": "CN"
},
{
"name": "Pioglitazone Hydrochloride",
"lang": "EN"
},
{
"name": "ピオグリタゾン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "恩格列净",
"lang": "CN"
},
{
"name": "Empagliflozin",
"lang": "EN"
... | null |
NCT02811016 | [
{
"id_field": "org_study_id",
"id_value": [
"M2016"
]
}
] | https://clinicaltrials.gov/study/NCT02811016 | Inhaled Budesonide and Acute Mountain Sickness | The primary objective of the study is to investigate the effect of inhaled budesonide on the incidence of AMS. The primary study question to ask is:<br/>1. Does inhaled budesonide reduce the incidence of AMS after rapid and active ascent to 4559 m?<br/>In addition, the secondary study questions to ask are:<br/>1. Does ... | Effect of Inhaled Budesonide on the Incidence and Severity of Acute Mountain Sickness at 4559 m | [
{
"description": "200 µg inhaled at 7:00 a.m. and 7 p.m.",
"name": "Budesonide 200",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pulmicort Turbohaler"
],
"type": "Drug"
},
{
"description": "800 µg inhaled at 7:00 a.m. and 7 p.m.",
"name": "Budeso... | [
{
"design_group_description": "inhaled budesonide 200 µg bid",
"design_group_title": "budesonide 200",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "200 µg inhaled at 7:00... | [
"Acute Mountain Sickness"
] | [
"Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft"
] | [
"University Hospital Heidelberg"
] | [
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"name": "ブデソニド",
"lang": "JP"
}
]
] | null |
NCT02467647 | [
{
"id_field": "org_study_id",
"id_value": [
"HLJDT-2016"
]
},
{
"id_field": "acronym",
"id_value": [
"HLJDT-2016"
]
}
] | https://clinicaltrials.gov/study/NCT02467647 | The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy | To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy. | Phase 1 Study of the Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy | [
{
"name": "Thalidomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "HLJDT",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Multiple Myeloma"
] | [
"Wuhan University"
] | [
"Shanghai Tongji Hospital"
] | [
[
{
"name": "沙利度胺",
"lang": "CN"
},
{
"name": "Thalidomide",
"lang": "EN"
},
{
"name": "サリドマイド（JAN）",
"lang": "JP"
}
],
[
{
"name": "黄连解毒汤",
"lang": "CN"
},
{
"name": "Huanglian JieDu Decoction",
"lang": "EN"
}
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "HLJDT-2016"
}
] |
NCT06503783 | [
{
"id_field": "org_study_id",
"id_value": [
"BL-M17D1-101"
]
},
{
"id_field": "secondary_id",
"id_value": [
"BL-M17D1-101"
]
}
] | https://clinicaltrials.gov/study/NCT06503783 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors | This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other soli... | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors | [
{
"description": "Administration by intravenous infusion for a cycle of 3 weeks.",
"name": "BL-M17D1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants receive BL-M17D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or oth... | [
"Breast Cancer",
"Solid Tumor"
] | [
"Sichuan Baili Pharmaceuticals Co.,Ltd"
] | [
"Baili Bio Chengdu Pharmaceutical Co. Ltd."
] | [
[
{
"name": "BL-M17D1",
"lang": "EN"
}
]
] | null |
NCT06343532 | [
{
"id_field": "org_study_id",
"id_value": [
"NIDA-SXC-Ph1b-001"
]
}
] | https://clinicaltrials.gov/study/NCT06343532 | SXC-2023 Cocaine Interaction Study | The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo. | Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral SXC-2023 | [
{
"description": "200 mg capsules",
"name": "SXC-2023",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "200 mg capsules",
"name": "SXC-2023 Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "SXC-2023: 800mg once a day for 7 days",
"design_group_title": "SXC-2023",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "200 mg capsules",
... | [
"Cocaine Use Disorder"
] | [
"National Institute on Drug Abuse"
] | [
"Technical Resources International, Inc.",
"Altasciences Co., Inc.",
"Promentis Pharmaceuticals, Inc."
] | [
[
{
"name": "SXC-2023",
"lang": "EN"
}
]
] | null |
NCT04721301 | [
{
"id_field": "org_study_id",
"id_value": [
"2017-003297-13"
]
}
] | https://clinicaltrials.gov/study/NCT04721301 | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | The study will be conducted in compliance with Good Clinical Practices (ICH-GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements, including archiving of essential documents. | LUMINESCENCE-001 Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer | [
{
"description": "In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc",
"name": "Nivolumab plus Ipilimumab plus Maraviroc",
"normalized_type": "26823d77f12d4744a960c336f01c2d6e",
"type": "Combination Product"
}
] | [
{
"design_group_description": "Treatment arm with Nivolumab, Ipilimumab and Maraviroc combination treatment",
"design_group_title": "Combination immunotherapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Colorectal Cancer Metastatic",
"Pancreatic Cancer Metastatic"
] | [
"University Hospital Heidelberg"
] | [
"German Cancer Research Center"
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | null |
NCT05239676 | [
{
"id_field": "org_study_id",
"id_value": [
"AUTO-CART-001"
]
}
] | https://clinicaltrials.gov/study/NCT05239676 | Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | Clinical Study on the Safety and Effectiveness of Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | [
{
"description": "The patient receives ECHOP chemotherapy or other chemotherapy regimens； G-CSF in the low cell stage mobilizes hematopoietic stem cells and freezes them for later use after collection； Autologous hematopoietic stem cells and prepared CD19 CAR-T cells are reinfused into the patient",
"name":... | [
{
"design_group_description": "Refractory and relapsed malignant lymphoma",
"design_group_title": "Treatment of Lymphoma",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Th... | [
"Lymphoma"
] | [
"Zhejiang University"
] | [
"Shanghai Yake Biotechnology Co., Ltd"
] | [
[
{
"name": "非格司亭 （安进）",
"lang": "CN"
},
{
"name": "Filgrastim (Amgen)",
"lang": "EN"
},
{
"name": "フィルグラスチム（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Anti-CD19 CART cell therapy (YaKe Biotechnology)",
"lang": "EN"
}
]
] | null |
NCT03763084 | [
{
"id_field": "org_study_id",
"id_value": [
"2018071027"
]
}
] | https://clinicaltrials.gov/study/NCT03763084 | Impact of Acetaminophen on Postoperative Delirium Elderly Patients After Non-cardiac Surgery | To investigate the impact of acetaminophen analgesia on the frequency of postoperative delirium and 28 days mortality in elderly patients after noncardiac surgery. | Impact of Oral Acetaminophen Analgesia on Postoperative Delirium and Long-term Survival in Elderly Patients After Non-cardiac Surgery: A Randomized Controlled Trial | [
{
"description": "For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.",
"name": "Acetaminophen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "For patients in the contro... | [
{
"design_group_description": "For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.",
"design_group_title": "acetaminophen",
"design... | [
"Acetaminophen",
"Delirium in Old Age"
] | [
"The Third Xiangya Hospital of Central South University"
] | [
"Yale University"
] | [
[
{
"name": "对乙酰氨基酚",
"lang": "CN"
},
{
"name": "Acetaminophen",
"lang": "EN"
},
{
"name": "アセトアミノフェン",
"lang": "JP"
}
]
] | null |
NCT07063030 | [
{
"id_field": "org_study_id",
"id_value": [
"SHGH-LX107"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SHGH-LX107"
]
}
] | https://clinicaltrials.gov/study/NCT07063030 | A Study of LX107 Gene Therapy in AIPL1-IRD Patients | Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety. | An Exploratory Clinical Study to Evaluate LX107 Gene Therapy in Patients With AIPL1 Biallelic Mutation-related Inherited Retinal Dystrophy (AIPL1-IRD) | [
{
"description": "Subjects will receive subretinal injection of LX107 on Day 0.",
"name": "LX107 Injection",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"type": "Genetic"
}
] | [
{
"design_group_description": "Experimental: LX107 Injection<br/>Arm Description:<br/>* Low dose group: subretinal injection of LX107 -3×10⁹ VG/eye<br/>* Medium dose group: subretinal injection of LX107- 1×10¹⁰ VG/eye<br/>* High dose group: subretinal injection of LX107 -3×10¹⁰ VG/eye",
"design_group_title"... | [
"Retinal Dystrophy"
] | [
"Shanghai First People's Hospital"
] | [
"Shanghai Langsheng Biotechnology Co., Ltd."
] | [
[
{
"name": "LX-107",
"lang": "EN"
}
]
] | null |
NCT06430684 | [
{
"id_field": "org_study_id",
"id_value": [
"SGLT2I-IN-KIDS"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"K23DK138313"
]
},
{
"id_field": "acronym",
"id_value": [
"SGLT2I-IN-KIDS"
]
},
{
"id_field": ... | https://clinicaltrials.gov/study/NCT06430684 | Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease | The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. Th... | Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease | [
{
"description": "Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older",
"name": "Empagliflozin 10 MG",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Empagliflozin 10mg daily for 3 months (n=20)",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Empagliflozi... | [
"Chronic Kidney Diseases",
"Pediatric Kidney Disease"
] | [
"Ann & Robert H. Lurie Children's Hospital of Chicago"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "恩格列净",
"lang": "CN"
},
{
"name": "Empagliflozin",
"lang": "EN"
},
{
"name": "エンパグリフロジン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SGLT2I-IN-KIDS"
}
] |
NCT05111509 | [
{
"id_field": "org_study_id",
"id_value": [
"202006288"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01CA243014"
]
}
] | https://clinicaltrials.gov/study/NCT05111509 | A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent | This is a first in man study to determine if [203Pb]VMT-?-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy in neuroendocrine therapy. | A Phase 0 First-in-human Clinical Trial of [203Pb]VMT-?-NET SPECT/CT for Somatostatin Receptor Imaging of Neuroendocrine Tumors | [
{
"description": "3 to 5 miliCuries of [203]Pb administered intravenously 60 minutes before the start of the scans.",
"name": "[203Pb]VMT-?-NET",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Scans are administered over 3 days: 1 hour post injecti... | [
{
"design_group_description": "injection of [203Pb]VMT-?-NET with serialized imaging and dosimetry measurements",
"design_group_title": "[203Pb]VMT-?-NET SPECT/CT",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Neuroendocrine Tumor Grade 2",
"Neuroendocrine Tumor Grade 1"
] | [
"University of Iowa"
] | [
"National Cancer Institute",
"The Holden Comprehensive Cancer Center",
"Perspective Therapeutics, Inc."
] | [
[
{
"name": "[203Pb]VMT-α-NET",
"lang": "EN"
}
]
] | null |
NCT06081153 | [
{
"id_field": "org_study_id",
"id_value": [
"852428"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HL166991"
]
}
] | https://clinicaltrials.gov/study/NCT06081153 | Mechanistic Clinical Trial of PCSK9 Inhibition for AAA | The goal of this mechanistic clinical trial is to assess whether lowering the low-density lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication evolocumab will have any effect on the tissue or cells of patients with abdominal aortic aneurysm (AAA). Researchers will compare participan... | A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm Repair | [
{
"description": "See arm description.",
"name": "Evolocumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "See arm description.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Evolocumab is the drug that will be administered in this study. It will be administered as a 140mg subcutaneous injection every 14 days for 5 weeks (for a total of 3 doses).",
"design_group_title": "Evolocumab",
"design_group_type": "Experimental",
"design_group_type_n... | [
"Abdominal Aortic Aneurysm"
] | [
"University of Pennsylvania"
] | [
"National Heart, Lung & Blood Institute",
"Amgen, Inc."
] | [
[
{
"name": "依洛尤单抗",
"lang": "CN"
},
{
"name": "Evolocumab",
"lang": "EN"
},
{
"name": "エボロクマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04740580 | [
{
"id_field": "org_study_id",
"id_value": [
"H48186"
]
}
] | https://clinicaltrials.gov/study/NCT04740580 | Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease | Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as ... | Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease | [
{
"description": "The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)",
"name": "Glycine",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"type": "Dietary Supplement"
},
{
"description": "The active arm will supplement a combination of glycine and N-... | [
{
"design_group_description": "Glycine and cysteine are amino-acid (protein) precursors of glutathione. Cysteine is provided as N-acetylcysteine",
"design_group_title": "Glycine plus N-acetylcysteine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22c... | [
"Alzheimer Disease"
] | [
"Baylor College of Medicine"
] | [
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "甘氨酸",
"lang": "CN"
},
{
"name": "Glycine",
"lang": "EN"
}
],
[
{
"name": "乙酰半胱氨酸",
"lang": "CN"
},
{
"name": "Acetylcysteine",
"lang": "EN"
},
{
"name": "アセチルシステイン",
"lang": "JP"
}
]
] | null |
NCT03153410 | [
{
"id_field": "org_study_id",
"id_value": [
"J1766"
]
},
{
"id_domain": "JHMIRB",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IRB00130267"
]
}
] | https://clinicaltrials.gov/study/NCT03153410 | Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer. | A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas | [
{
"description": "200 mg/m^2, intravenous (IV) infusion<br/>Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later,... | [
{
"design_group_title": "Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "75 mg (dose level 1) or 100 mg (dose level 2), intra... | [
"Pancreatic Cancer"
] | [
"The Sidney Kimmel Comprehensive Cancer Center"
] | [
"Merck Sharp & Dohme Corp.",
"Eli Lilly & Co."
] | [
[
{
"name": "LY-3022855",
"lang": "EN"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "GVAX vaccine(The Sidney Kimmel Comp... | null |
NCT03122639 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAR0444"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"2R01HL106041-06A1"
]
}
] | https://clinicaltrials.gov/study/NCT03122639 | Endothelial Function in Obstructive Sleep Apnea | Obstructive sleep apnea (OSA), a condition that affects a quarter of the Western adults, triples the risk for cardiovascular diseases and increases all-cause mortality. Intermittent hypoxia (IH) during transient cessation of breathing in OSA leads to endothelial inflammation, a key step in the initiation and progressio... | Vascular Endothelial Activation in Obstructive Sleep Apnea | [
{
"description": "Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in pr... | [
{
"design_group_description": "OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).",
"design_group_title": "Treatment",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f2... | [
"Obstructive Sleep Apnea of Adult"
] | [
"Columbia University"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "阿托伐他汀钙",
"lang": "CN"
},
{
"name": "Atorvastatin Calcium",
"lang": "EN"
},
{
"name": "アトルバスタチンカルシウム水和物",
"lang": "JP"
}
]
] | null |
NCT03477110 | [
{
"id_field": "org_study_id",
"id_value": [
"17P.346"
]
},
{
"id_domain": "JeffTrial Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"JT 10706"
]
}
] | https://clinicaltrials.gov/study/NCT03477110 | Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma | This pilot early phase I trial studies the side effects of temozolomide, radiation therapy, and tumor treating fields therapy using Novo tumor treatment fields (TTF)-200A device in participants with glioblastoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,... | SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study | [
{
"description": "Given PO",
"name": "Temozolomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"362856",
"Methazolastone",
"Temcad",
"Temodal",
"Temodar"
],
"type": "Drug"
},
{
"description": "Undergo radiation therapy",
... | [
{
"design_group_description": "Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment field... | [
"Glioblastoma"
] | [
"Sidney Kimmel Cancer Center at Thomas Jefferson University"
] | [
"NovoCure Ltd."
] | [
[
{
"name": "替莫唑胺",
"lang": "CN"
},
{
"name": "Temozolomide",
"lang": "EN"
},
{
"name": "テモゾロミド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "3950e882a345024a522248ee2a2a2da8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CTNI-21"
},
{
"identifier_source": [
{
"code": "024a8d88de2920205050523349a53a25",
"source": "CT_RESULT_A... |
NCT03815084 | [
{
"id_field": "org_study_id",
"id_value": [
"PD-1/DC-NK YNYY-01"
]
}
] | https://clinicaltrials.gov/study/NCT03815084 | A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors | clinical study on the safety and efficacy of PD1 combined with dc-Nk in the treatment of solid tumors | Clinical Study on the Safety and Efficacy of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors | [
{
"description": "total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .",
"name": "pd-1 and DC-NK cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
... | [
{
"design_group_title": "PD-1 and DC-NK treatment group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at da... | [
"Solid Tumor"
] | [
"Beijing Allife Medicine Technology Co., Ltd."
] | [
"Henan Provincial Peoples Hospital",
"Beijing Hospital of the Ministry of Health"
] | [
[
{
"name": "DC-NK cells(Allife Medicine Technology)",
"lang": "EN"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT05747469 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00002134"
]
}
] | https://clinicaltrials.gov/study/NCT05747469 | Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand | The purpose the research is to evaluate the safety and efficacy of injection of adipose allograft matrix (AAM) to the small joints of the hand for treatment of early stage osteoarthritis. The hypothesis is that use of AAM injected directly into the joint will show improvements in pain and disability while providing a s... | Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand | [
{
"description": "Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.",
"name": "local anaesthetic injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lidocaine"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "Using fluoroscopic guidance (X-ray), a needle will be injected into the joint space. 1 cc of Leneva (adipose allograft matrix, MTF Biologics) will be injected into the joint.",
"design_group_title": "Adipose Allograft Matrix (AAM)",
"design_group_type": "Other",
"inter... | [
"Osteoarthritis Hand"
] | [
"Cedars-Sinai Medical Center"
] | [
"Musculoskeletal Transplant Foundation"
] | [
[
{
"name": "利多卡因",
"lang": "CN"
},
{
"name": "Lidocaine",
"lang": "EN"
},
{
"name": "リドカイン",
"lang": "JP"
}
]
] | null |
NCT06212271 | [
{
"id_field": "org_study_id",
"id_value": [
"854429"
]
},
{
"id_field": "secondary_id",
"id_value": [
"854429"
]
}
] | https://clinicaltrials.gov/study/NCT06212271 | Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease | The goal of this mechanistic clinical trial is to test the effects of reducing inflammatory signaling in femoral artery atherosclerotic plaques. Researchers will compare patients receiving colchicine to patients receiving placebo to determine the effect of colchicine on the inflammatory state of atherosclerotic femoral... | A Randomized, Placebo-Controlled Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease | [
{
"description": "See arm description.",
"name": "Colchicine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "See arm description.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Colchicine (0.6 mg oral daily for 4-weeks) will be the drug administered in this study.",
"design_group_title": "Colchicine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Peripheral Artery Disease"
] | [
"University of Pennsylvania"
] | [
"Doris Duke Foundation"
] | [
[
{
"name": "秋水仙碱",
"lang": "CN"
},
{
"name": "Colchicine",
"lang": "EN"
},
{
"name": "コルヒチン",
"lang": "JP"
}
]
] | null |
NCT06212388 | [
{
"id_field": "org_study_id",
"id_value": [
"GDT-001-08"
]
}
] | https://clinicaltrials.gov/study/NCT06212388 | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in neoadjuvant treatment of patients with Stage III-IV resectable melanoma. | Efficacy and Safety of Allogeneic γδ T Cells (γδ T Cells) Combined With Interferon-alpha1b (IFN-α1b) or PD-1 Monoclonal Antibody in Neoadjuvant Treatment of Stage III-IV Resectable Melanoma | [
{
"description": "Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.",
"name": "Ex-vivo expanded allogeneic γδ T cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
... | [
{
"design_group_description": "Stage 1: Neoadjuvant stage (Week 1-9, 3 cycles)<br/>Stage 2: Surgical period (2 weeks, ±7 days after the last dose of neoadjuvant therapy) After multidisciplinary MDT team evaluation, the primary lesion and metastasis were resected in the corresponding departments.<br/>Stage 3: Po... | [
"Melanoma"
] | [
"Xijing Hospital"
] | [
"Beijing Jiadehe Cell Therapy Technology Co., Ltd"
] | [
[
{
"name": "Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology)",
"lang": "EN"
}
]
] | null |
NCT03599453 | [
{
"id_field": "org_study_id",
"id_value": [
"I 62218"
]
}
] | https://clinicaltrials.gov/study/NCT03599453 | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | This pilot trial studies how well chemokine modulation therapy works when given prior to pembrolizumab in treating participants with triple-negative breast cancer that has spread to other places in the body. Drugs used in chemokine modulation therapy, such as celecoxib, recombinant interferon alfa-2b, and rintatolimod,... | Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | [
{
"description": "Undergo Biopsy",
"name": "Biopsy",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"type": "Procedure"
},
{
"description": "Undergo chemokine modulation therapy",
"name": "Chemokine Modulation Therapy",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
... | [
{
"design_group_description": "Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo ad... | [
"Triple -Negative Breast Cancer",
"Estrogen Receptor Negative",
"HER2/Neu Negative",
"Anatomic Stage IV Breast Cancer AJCC",
"Progesterone Receptor Negative"
] | [
"Roswell Park Comprehensive Cancer Center"
] | [
"AIM ImmunoTech, Inc."
] | [
[
{
"name": "重组人干扰素α-2b(Merck Sharp & Dohme )",
"lang": "CN"
},
{
"name": "INTERFERON ALFA-2B(Merck Sharp & Dohme )",
"lang": "EN"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"na... | null |
NCT04723862 | [
{
"id_field": "org_study_id",
"id_value": [
"HSR200015"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HD102060"
]
},
{
"id_field": "acronym",
"id_value": [
"CBS010"
]
}
] | https://clinicaltrials.gov/study/NCT04723862 | Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism? | The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism (HA), androgen-receptor blockade (spironolactone) alone normalizes sleep-wake luteinizing hormone (LH) pulse frequency (primary endpoint) and overall LH and follicle-stimulating hormone secretion (secondary endpoints). | Does Spironolactone Normalize Sleep-wake Luteinizing Hormone (LH) Pulse Frequency in Pubertal Girls With Hyperandrogenism? (CBS010) | [
{
"description": "Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).",
"name": "Spironolactone",
"normalized_type": "3d1aa88261d64c03... | [
{
"design_group_description": "Prior to the first or second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).",
"design_group_title": "Spironolactone",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b556... | [
"Hyperandrogenism",
"Polycystic Ovary Syndrome",
"Puberty"
] | [
"University of Virginia"
] | [
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "螺内酯",
"lang": "CN"
},
{
"name": "Spironolactone",
"lang": "EN"
},
{
"name": "スピロノラクトン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CBS010"
}
] |
NCT07381582 | [
{
"id_field": "org_study_id",
"id_value": [
"PUMCH-MCH-161Tb-LNC1011"
]
},
{
"id_field": "acronym",
"id_value": [
"161Tb-LNC1011"
]
},
{
"id_field": "secondary_id",
"id_value": [
"PUMCH-MCH-161Tb-LNC1011"
]
}
] | https://clinicaltrials.gov/study/NCT07381582 | Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | This is a prospective, open-label, single-center, dose-escalation study using a standard 3+3 design to assess the safety, tolerability, biodistribution/dosimetry and preliminary efficacy of the albumin-binding PSMA radioligand 161Tb-LNC1011 in patients with metastatic castration-resistant prostate cancer (mCRPC). Patie... | A Prospective, Open-label, Dose-Escalation, Single-Center Study to Evaluate the Safety, Biodistribution/Dosimetry and Preliminary Efficacy of 161Tb-LNC1011 in Patients With Metastatic Castration-Resistant Prostate Cancer | [
{
"description": "Intravenous administration; planned dose levels: 50, 80, 130, 200 mCi (±10%); cycle interval q6 weeks; up to 1 cycle at 50 mCi and up to 4 cycles at later dose levels as permitted by safety and disease status.",
"name": "161Tb-LNC1011",
"normalized_type": "3d1aa88261d64c038413723970f2b... | [
{
"design_group_description": "Single-group, open-label, sequential dose escalation of 161Tb-LNC1011 (IV). Planned dose levels: 50, 80, 130, 200 mCi (±10%). At 50 mCi: 1 cycle; higher levels: up to 4 cycles every 6 weeks, contingent on safety and disease status. DLT window: 6 weeks post-dose; MTD per standard 3... | [
"Prostate Cancer"
] | [
"Peking Union Medical College Hospital"
] | [
"Mianyang Central Hospital"
] | [
[
{
"name": "161Tb-LNC1011",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "161Tb-LNC1011"
}
] |
NCT03575598 | [
{
"id_field": "org_study_id",
"id_value": [
"SNOW-001"
]
},
{
"id_field": "acronym",
"id_value": [
"SNOW"
]
}
] | https://clinicaltrials.gov/study/NCT03575598 | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study | This is a window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative drugs, Sitravatinib and Nivolumab. | Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW) | [
{
"description": "Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.",
"name": "Sitravatinib",
"normalized_type": "3d1aa88261d64c038413723... | [
{
"design_group_description": "Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.<br/>Nivolumab will be given as a single infusion at a d... | [
"Squamous Cell Carcinoma, Head And Neck",
"Squamous Cell Carcinoma Mouth",
"Squamous Cell Carcinoma of the Oral Cavity"
] | [
"University Health Network"
] | [
"Mirati Therapeutics, Inc."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "司曲替尼",
"lang": "CN"
},
{
"name": "Sitravatinib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5949520295e2a55a24d8532029eed8aa",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a9258025805588229242228a4e909242",
"s... |
NCT02037035 | [
{
"id_field": "org_study_id",
"id_value": [
"1305011972"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1K23MH101498-01"
]
}
] | https://clinicaltrials.gov/study/NCT02037035 | Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling | This study is looking at the mechanisms underlying the behavioral effects of ketamine in healthy and depressed individuals. | Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling | [
{
"name": "Ketamine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Healthy participants will receive ketamine in the scan",
"design_group_title": "Healthy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Ketamine",
... | [
"Depression"
] | [
"Yale University"
] | [
"American Psychiatric Association",
"National Institute of Mental Health"
] | [
[
{
"name": "盐酸氯胺酮",
"lang": "CN"
},
{
"name": "Ketamine Hydrochloride",
"lang": "EN"
},
{
"name": "ケタミン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT06224049 | [
{
"id_field": "org_study_id",
"id_value": [
"BGI-006"
]
},
{
"id_domain": "Ethics Committee of Shenzhen University General Hospital",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"KYLLHS-20230102C"
]
},
{
"id_field": "acronym",
... | https://clinicaltrials.gov/study/NCT06224049 | Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T | Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma.<br/>Secondary objective: To evaluate the effectiveness of hNeo-T injection, and to evaluate the objective response rate (ORR) and disease control rate (DCR) by Lugano2014 criteria... | A Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Targeted Haploidentical Neoantigen T Cell Injection (hNeo-T) in the Treatment of Relapsed or Refractory EBV-positive T-cell Lymphoma | [
{
"description": "After subject screening, peripheral blood mononuclear cell （PBMC） donors matching half or more of the subject's HLA matching will undergo blood collection to prepare hNeo-T. hNeo-T preparation is expected to be 25-30 days after blood collection. In this study, the bridging therapy will be allo... | [
{
"design_group_description": "The escalating doses of hNeo-T in this study will be 5*10^7 cells and1*10^8 cells.",
"design_group_title": "hNeo-T",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"inter... | [
"T-cell Lymphoma"
] | [
"BGI Genomics Co., Ltd."
] | [
"Shenzhen University General Hospital"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "GI-hNeoT-01"
}
] |
NCT00894283 | [
{
"id_field": "org_study_id",
"id_value": [
"NA_00025492"
]
}
] | https://clinicaltrials.gov/study/NCT00894283 | Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients | This pilot study is designed to determine the feasibility of conducting a randomized clinical trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice daily with respect to preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after bariatric surgery in obese patients. | A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily With Respect to Preventing VTE After Bariatric Surgery in Obese Patients | [
{
"description": "Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.",
"name": "Enoxaparin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": ... | [
{
"design_group_description": "Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.",
"design_group_title": "Enoxaparin",
"design_group_type": "Active Comparator"... | [
"Deep Venous Thrombosis",
"Pulmonary Embolism"
] | [
"The Johns Hopkins University"
] | [
"GSK Plc"
] | [
[
{
"name": "磺达肝癸钠",
"lang": "CN"
},
{
"name": "Fondaparinux Sodium",
"lang": "EN"
},
{
"name": "フォンダパリヌクスナトリウム",
"lang": "JP"
}
],
[
{
"name": "依诺肝素钠",
"lang": "CN"
},
{
"name": "Enoxaparin Sodium",
"lang": "EN"
... | null |
NCT00708994 | [
{
"id_field": "org_study_id",
"id_value": [
"0803003638"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R21DA020750-02"
]
},
{
"id_field": "acronym",
"id_value": [
"THC-Gamma"
]
}
] | https://clinicaltrials.gov/study/NCT00708994 | Cannabinoids, Neural Synchrony, and Information Processing | The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony. Neural synchrony is studied using electroencephalography (EEG). | Cannabinoids, Psychosis, Neural Synchrony, and Information Processing | [
{
"description": "* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.<br/>* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a mariju... | [
{
"design_group_description": "* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.<br/>* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4t... | [
"Cannabis",
"Psychotic Disorders"
] | [
"Yale University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "屈大麻酚",
"lang": "CN"
},
{
"name": "Dronabinol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "THC-Gamma"
}
] |
NCT02766270 | [
{
"id_field": "org_study_id",
"id_value": [
"CFMD 2016-2-1073"
]
}
] | https://clinicaltrials.gov/study/NCT02766270 | CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas | The management of lower-grade gliomas (Diffuse low-grade and intermediate-grade gliomas, WHO II and III) is largely based on surgery followed by radiotherapy. Recent studies showed that lower-grade glioma patients with IDH wild-type (IDH-wt) and TERT promoter mutation (TERTp-mut) had dismal clinical outcomes. These res... | A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas | [
{
"description": "RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).",
"name": "Temozolomide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
... | [
{
"design_group_description": "Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and... | [
"Grade II/III Glioma"
] | [
"Beijing Tiantan Hospital"
] | [
"Beijing Neurosurgical Institute",
"Capital University of Medical Sciences"
] | [
[
{
"name": "替莫唑胺",
"lang": "CN"
},
{
"name": "Temozolomide",
"lang": "EN"
},
{
"name": "テモゾロミド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "4e0d5aae48855825d9e33929e82daa5a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ACTR-14"
}
] |
NCT03219047 | [
{
"id_field": "org_study_id",
"id_value": [
"2017-0051"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2018-01117"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03219047 | Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | This early phase I pilot trial studies how well patient-derived xenografts work in personalizing treatment for patients with mantle cell lymphoma that has come back (relapsed) or that isn't responding to treatment (refractory). Xenograft models involve taking a piece of tissue from a tumor that was previously collected... | A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE Trial | [
{
"description": "Receive standard of care",
"name": "Best Practice",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"other_name": [
"standard of care",
"standard therapy"
],
"type": "Other"
},
{
"description": "Given at standard dose and schedule",
"name": "I... | [
{
"design_group_description": "Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. P... | [
"Recurrent Mantle Cell Lymphoma",
"Refractory Mantle Cell Lymphoma"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "伊布替尼",
"lang": "CN"
},
{
"name": "Ibrutinib",
"lang": "EN"
},
{
"name": "イブルチニブ",
"lang": "JP"
}
]
] | null |
NCT03493178 | [
{
"id_field": "org_study_id",
"id_value": [
"H42035: Glutathione in MCI"
]
}
] | https://clinicaltrials.gov/study/NCT03493178 | Glutathione in Mild Cognitive Impairment | Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanisms linked to GSH for cognitive impairment (and improvement) by studying... | Glutathione in Mild Cognitive Impairment | [
{
"description": "Dietary Supplement: glycine will be supplemented in the active arm for 12-weeks",
"name": "Glycine",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"type": "Dietary Supplement"
},
{
"description": "Dietary Supplement: NAC will be supplemented in the active arm for 1... | [
{
"design_group_description": "30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provide... | [
"Mild Cognitive Impairment"
] | [
"Baylor College of Medicine"
] | [
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "甘氨酸",
"lang": "CN"
},
{
"name": "Glycine",
"lang": "EN"
}
]
] | null |
NCT02181478 | [
{
"id_field": "org_study_id",
"id_value": [
"CASE1Z14"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2014-01316"
]
},
{
"id_domain": "Case Comprehensive Cancer Ce... | https://clinicaltrials.gov/study/NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone... | Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study | [
{
"description": "All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6",
"name": "cyclophosphamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CPM",
"CTX",
"Cytoxan",
"Endoxan",
"Endoxana"
],
"type": ... | [
{
"design_group_description": "REDUCED INTENSITY CONDITIONING (RIC):<br/>Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.<br/>Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single ... | [
"Acute Lymphoblastic Leukemia",
"Acute Myelogenous Leukemia",
"Myelodysplastic Syndromes",
"Myelofibrosis",
"Relapsed Non-Hodgkin Lymphoma",
"Refractory Non-Hodgkin Lymphoma",
"Hodgkin Lymphoma",
"Refractory Hodgkin Lymphoma",
"Relapsed Chronic Lymphocytic Leukemia",
"Refractory Chronic Lymphocyti... | [
"The Case Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT05816785 | [
{
"id_field": "org_study_id",
"id_value": [
"2022-1590"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01CA262292-01A1"
]
},
{
"id_domain": "CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
... | https://clinicaltrials.gov/study/NCT05816785 | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer | The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery to remove your tumor... | A Pilot Window of Opportunity Study of Imatinib in Combination With Cetuximab in Patients With Squamous Cell Carcinomas of the Head and Neck | [
{
"description": "Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2",
"name": "Cetuximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "400 mg orally daily",
"name": "Imatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Participants will receive two doses of CTX and a minimum of an 8 day (maximum 14 day) course of imatinib prior to definitive surgery or definitive radiation/chemoradiation.",
"design_group_title": "Imatinib Cetuximab Combination",
"design_group_type": "Experimental",
"... | [
"Head and Neck Cancer",
"Squamous Cell Carcinoma of Head and Neck"
] | [
"University of Wisconsin-Madison"
] | [
"National Cancer Institute"
] | [
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "甲磺酸伊马替尼",
"lang": "CN"
},
{
"name": "Imatinib mesylate",
"lang": "EN"
},
... | null |
NCT05008146 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY20060171 (Aim 1)"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA026472"
]
},
{
"id_domain": "University of Pittsburgh",
"id_field": "secondary_id",
"id_type": ... | https://clinicaltrials.gov/study/NCT05008146 | Imaging CRF X NOP Interactions in CUD | This study uses [11C]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examin... | Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1) | [
{
"description": "Radiotracer",
"name": "Baseline [C-11]NOP-1A PET Scan",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"type": "Radiation"
},
{
"description": "Intravenous, 1mg/Kg",
"name": "Hydrocortisone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type":... | [
{
"design_group_description": "[C-11]NOP-1A",
"design_group_title": "PET",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Radiotracer",
"intervention_name": "Baseli... | [
"Cocaine Use Disorder"
] | [
"University of Pittsburgh"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "氢化可的松",
"lang": "CN"
},
{
"name": "Hydrocortisone",
"lang": "EN"
},
{
"name": "ヒドロコルチゾン",
"lang": "JP"
}
]
] | null |
NCT05780216 | [
{
"id_field": "org_study_id",
"id_value": [
"DMT-HAR-MED"
]
}
] | https://clinicaltrials.gov/study/NCT05780216 | Mindfulness and Psychedelics | The investigators are doing this project to investigate potential neurophysiological synergy effects between mindfulness meditation and psychedelics. Previous studies have found that both mindfulness and psychedelics like psilocybin modulate neural activity and connectivity of the same brain network. However, little is... | Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators | [
{
"description": "The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.",
"name": "DMT + harmine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Th... | [
{
"design_group_description": "This arm comprises the following interventions:<br/>* Mindfulness Intervention in the course of the meditation group retreat<br/>* Administration of DMT + harmine (moderate-high dose)",
"design_group_title": "DMT and harmine",
"design_group_type": "Experimental",
"desi... | [
"Healthy Participants"
] | [
"Psychiatric Hospital of The University of Zurich"
] | [
"University Medical Center Freiburg"
] | [
[
{
"name": "二甲基色胺",
"lang": "CN"
},
{
"name": "Dimethyltryptamine",
"lang": "EN"
}
],
[
{
"name": "肉叶云香碱",
"lang": "CN"
},
{
"name": "Telepathine",
"lang": "EN"
}
]
] | null |
NCT05478863 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00330923"
]
}
] | https://clinicaltrials.gov/study/NCT05478863 | The Pharmacodynamics of Cannabinoid-Caffeine Combinations | Cannabis and caffeine are two of the most commonly consumed psychoactive substances in the world, with many consumers reporting positive impacts on energy, alertness, and focus. Preliminary evidence has suggested that cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, may mitigate the negative side ... | A Double-Blind, Randomized, Placebo-Controlled, Within-Subject Crossover Study of the Effects of Combinations of Cannabinoids and Caffeine | [
{
"description": "Placebo will be orally self-administered by study participants.",
"name": "Oral Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "THC will be orally self-administered by study participants.",
"name": "Oral THC",
"no... | [
{
"design_group_description": "Acute administration of oral placebo three times in study session (Time 0, 60, and 120).",
"design_group_title": "Oral placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
... | [
"Behavioral Pharmacology of Cannabinoids"
] | [
"The Johns Hopkins University"
] | [
"Canopy Growth Corp."
] | [
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
],
[
{
"name": "咖啡因",
"lang": "CN"
},
{
"name": "Caffeine",
"lang": "EN"
},
{
"name": "カフェイン水和物",
"lang": "JP"
}
],
[
{
"n... | null |
NCT05472818 | [
{
"id_field": "org_study_id",
"id_value": [
"2000032181"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01DA054314"
]
},
{
"id_field": "secondary_id",
"id_value": [
"1R01DA054314;2000032181"
]
}
] | https://clinicaltrials.gov/study/NCT05472818 | SV2A Density Cannabis Use Disorder | The main purpose of this study is to determine whether hippocampal synaptic vesicle density estimated by hippocampal [11C]APP-311/[11C]UCB-J binding in individuals diagnosed with cannabis use disorder (CUDs) improves with at least 4 weeks of confirmed abstinence from cannabis, in comparison to healthy controls (HCs). F... | SV2A Density Cannabis Use Disorder | [
{
"description": "For each [11C]APP311 (UCB-J) PET scan, up to 20 mCi of [11C]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third [11C]APP31... | [
{
"design_group_description": "Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart. CUD participants will be asked to abstain from cannabis for the 4 week period.",
"design_group_title": "CUD Group",
"design_g... | [
"Cannabis Use Disorder",
"Healthy"
] | [
"Yale University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "11C-UCB-J",
"lang": "EN"
}
]
] | null |
NCT06273852 | [
{
"id_field": "org_study_id",
"id_value": [
"PBL-0405-01"
]
}
] | https://clinicaltrials.gov/study/NCT06273852 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device. | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | [
{
"description": "Intratumoral microdose injection by the CIVO device.",
"name": "PBA-0405",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"PB004.22.0405.aF"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected at 1-2 days prior to surgery using the CIVO device. Each needle of the CIVO device will deliver up to 8.3 microliters of solution, including a vehicle control (sterile saline) or subtherapeu... | [
"Head and Neck Squamous Cell Carcinoma",
"Soft Tissue Sarcoma Adult",
"Triple Negative Breast Cancer"
] | [
"Pure Biologics SA"
] | [
"Presage Biosciences, Inc."
] | [
[
{
"name": "PBA-0405",
"lang": "EN"
}
]
] | null |
NCT07458659 | [
{
"id_field": "org_study_id",
"id_value": [
"TTCI-BCMA-MM-P1b-2026"
]
},
{
"id_field": "acronym",
"id_value": [
"CART-BCMA"
]
},
{
"id_field": "secondary_id",
"id_value": [
"TTCI-BCMA-MM-P1b-2026"
]
}
] | https://clinicaltrials.gov/study/NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma. | Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | [
{
"description": "This product is a CAR T-cell therapy utilizing the participant's own autologous T-lymphocytes, which are collected via apheresis, processed in a laboratory setting, and subsequently reinfused intravenously through a peripheral vein at a rate of 2-5 mL/min. Participants will undergo cell collec... | [
{
"design_group_description": "Chimeric antigen receptor T-cell injection targeting BCMA (CART-BCMA) Dose level: 0.5×10e7 cells/Kg",
"design_group_title": "CART-BCMA in multiple myeloma",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Relapsed/Refractory Multiple Myeloma (MM)"
] | [
"University of Chulalongkorn"
] | [
"University of Chulalongkorn",
"King Chulalongkorn Memorial Hospital"
] | [
[
{
"name": "BCMA-Targeted CAR T-Cell(Chulalongkorn University)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CART-BCMA"
}
] |
NCT04380831 | [
{
"id_field": "org_study_id",
"id_value": [
"20006"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2020-02744"
]
},
{
"id_domain": "City of Hope Medical Center",
... | https://clinicaltrials.gov/study/NCT04380831 | TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | This early phase I trial studies the side effects and feasibility of total body irradiation using intensity modulation radiation therapy (IMRT) when given in combination with cyclophosphamide prior to stem cell transplant to treat severe systemic sclerosis. IMRT delivers total body radiation therapy more precisely and ... | Pilot Study of Total Body Irradiation Using Intensity Modulated Radiation Therapy (IMRT) and Cyclophosphamide Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation in Patients With Severe Systemic Sclerosis | [
{
"description": "Undergo HSCT",
"name": "Allogeneic Hematopoietic Stem Cell Transplantation",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"Allogeneic Hematopoietic Cell Transplantation",
"HSC",
"HSCT",
"Stem Cell Transplantation, Allogeneic",
... | [
{
"design_group_description": "Patients undergo TBI using IMRT BID on days -5 and -4 in the absence of disease progression or disease progression. Patients then receive cyclophosphamide on days -3 and -2 and undergo HSCT on day 0 in the absence of disease progression or unacceptable toxicity.",
"design_grou... | [
"Systemic Scleroderma"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
]
] | null |
NCT05852041 | [
{
"id_field": "org_study_id",
"id_value": [
"NU 22U05"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2023-02187"
]
},
{
"id_field": "secondary_id",
"id_value"... | https://clinicaltrials.gov/study/NCT05852041 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candi... | A Pilot Study of rhPSMA-PET MRI Imaging for the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | [
{
"description": "Undergo MRI/PET prostate biopsy",
"name": "Biopsy of Prostate",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"other_name": [
"Prostate Biopsy",
"Prostatic Biopsy"
],
"type": "Procedure"
},
{
"description": "Undergo decipher",
"name": "Decip... | [
{
"design_group_description": "Patients receive rhPSMA-7.3 IV then undergo PET-MRI and mpMRI of the prostate on study. Patients also undergo Decipher test at screening and MRI-PET prostate biopsy or radical prostatectomy within 90 days per standard of care.",
"design_group_title": "Treatment (rhPSMA, PET-MR... | [
"Prostate Adenocarcinoma",
"Stage I Prostate Cancer AJCC v8",
"Stage IIA Prostate Cancer AJCC v8",
"Stage IIB Prostate Cancer AJCC v8"
] | [
"Northwestern University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "氟[18F]妥司特",
"lang": "CN"
},
{
"name": "Flotufolastat F-18",
"lang": "EN"
}
]
] | null |
NCT03380936 | [
{
"id_field": "org_study_id",
"id_value": [
"17-1812"
]
}
] | https://clinicaltrials.gov/study/NCT03380936 | Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients | This is a pilot study to determine if extended release Envarsus at an optimal level is just as effective as more invasive standard therapies for subclinical (mild) AMR (antibody mediated rejection) in kidney transplant patients. Subjects will be randomized to either conversion to Envarsus XR (extended release); or, to ... | A Randomized Pilot Study of Treatment for Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients | [
{
"description": "Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to ... | [
{
"design_group_description": "Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet [Envarsus]) with goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol",
"... | [
"Kidney Transplant Rejection"
] | [
"University of Colorado Denver"
] | [
"Veloxis Pharmaceuticals A/S"
] | [
[
{
"name": "他克莫司",
"lang": "CN"
},
{
"name": "Tacrolimus",
"lang": "EN"
},
{
"name": "タクロリムス水和物",
"lang": "JP"
}
],
[
{
"name": "利妥昔单抗",
"lang": "CN"
},
{
"name": "Rituximab",
"lang": "EN"
},
{
"name":... | null |
NCT03837470 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB_00112270"
]
},
{
"id_field": "acronym",
"id_value": [
"ERES-HFpEF"
]
}
] | https://clinicaltrials.gov/study/NCT03837470 | Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction | Heart failure (HF) affects 2-3% of the population, and is characterized by impaired sodium balance which results in fluid overload. Ejection fraction, a measure of systolic function, is reduced in only about half of all HF patients. Incidence of heart failure with preserved ejection fraction (HFpEF) has increased in th... | Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction | [
{
"description": "Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes",
"name": "0.9% Sodium Chloride",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"normal saline"
],
"type": "Drug"
},
{
"description":... | [
{
"design_group_description": "Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg",
"design_group_title": "Saline Loading and Diuretic Challenge",
"design_group_type": "Experimental",
"design_group_type_normalized_id... | [
"Heart Failure With Preserved Ejection Fraction"
] | [
"University of Utah"
] | [
"University of Utah"
] | [
[
{
"name": "呋塞米",
"lang": "CN"
},
{
"name": "Furosemide",
"lang": "EN"
},
{
"name": "フロセミド",
"lang": "JP"
}
],
[
{
"name": "氯化钠",
"lang": "CN"
},
{
"name": "Sodium Chloride",
"lang": "EN"
},
{
"name": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ERES-HFpEF"
}
] |
NCT06645808 | [
{
"id_field": "org_study_id",
"id_value": [
"VAR2-2024-CS01"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-513827-18-00"
]
},
{
"id_field": "acronym",
"id_value": [
"VARTUTRACE"
]
}
] | https://clinicaltrials.gov/study/NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors | VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).<br/>Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identif... | The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial | [
{
"description": "89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.",
"name": "89Zr-DFO-N-Suc-F8scFv",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "89-Zirconium labeled short-chain variable fragment C9 targeting ... | [
{
"design_group_description": "The first 3 patients of this arm will receive a single i.v. microdose (1 mg) administration of 89Zr-F8scFv 15 MBq, followed by three whole-body PET/CT scans on day 1, 2 and 4. After the first three patients, an interim analysis will be conducted to determine the optimal scanning t... | [
"Solid Tumor",
"Colon Carcinoma",
"Rectal Carcinoma",
"Osteosarcoma",
"Chondrosarcoma",
"Lung Carcinoma",
"Head and Neck Squamous Cell Carcinoma",
"Esophageal Carcinoma",
"Gastric Carcinoma",
"Pancreas Carcinoma",
"Bladder Carcinoma",
"Glioblastoma",
"Soft Tissue Sarcoma (STS)",
"Breast Ca... | [
"Var2 Pharmaceutical"
] | [
"Tracer Europe BV"
] | [
[
{
"name": "Zirconium-89 Labelled Vartumab",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "VARTUTRACE"
}
] |
NCT07275736 | [
{
"id_field": "org_study_id",
"id_value": [
"HY001021"
]
},
{
"id_field": "secondary_id",
"id_value": [
"HY001021"
]
}
] | https://clinicaltrials.gov/study/NCT07275736 | A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases | This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of CNCT19 cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases. | An Exploratory Clinical Study on the Safety and Efficacy of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Autoimmune Neurological Diseases | [
{
"description": "A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.",
"name": "CNCT19 cell injection",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_title": "Single dose of CNCT19",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be ... | [
"Neurological Autoimmune Diseases"
] | [
"Juventas Cell Therapy Ltd."
] | [
"Beijing Tiantan Hospital"
] | [
[
{
"name": "纳基奥仑赛",
"lang": "CN"
},
{
"name": "Inaticabtagene Autoleucel",
"lang": "EN"
}
]
] | null |
NCT00663910 | [
{
"id_field": "org_study_id",
"id_value": [
"CASE-9Z07-CC417"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA043703"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
... | https://clinicaltrials.gov/study/NCT00663910 | Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer | RATIONALE: Studying samples of tumor tissue in the laboratory from patients with nonmelanoma skin cancer that has been treated with topical aminolevulinic acid may help doctors predict how patients will respond to photodynamic therapy.<br/>PURPOSE: This clinical trial is studying topical aminolevulinic acid in patients... | Evaluation of Protoporphyrin Formation in Non-Melanoma Skin Cancers After Topical Application of 5-Aminolevulinic Acid: A Pilot Study | [
{
"description": "On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enou... | null | [
"Non-melanomatous Skin Cancer"
] | [
"The Cleveland Clinic Foundation"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸氨酮戊酸",
"lang": "CN"
},
{
"name": "Aminolevulinic Acid Hydrochloride",
"lang": "EN"
},
{
"name": "アミノレブリン酸塩酸塩",
"lang": "JP"
}
]
] | null |
NCT04939337 | [
{
"id_field": "org_study_id",
"id_value": [
"20181231"
]
}
] | https://clinicaltrials.gov/study/NCT04939337 | A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease. | The purpose of this study is to asses the efficacy and Safety of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Complex Perianal Fistula in Perianal Crohn's Disease. | Study to Assess the Safety and Efficacy of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells(TH-SC01), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease. | [
{
"description": "Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)",
"name": "TH-SC01",
"normalized_type": "3d1aa88261d64c038413723970f2b58b... | [
{
"design_group_description": "TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.",
"design_group_title": "TH-SC01",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Crohn's Disease"
] | [
"Nanjing General Hospital of Nanjing Military Command"
] | [
"Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd."
] | [
[
{
"name": "人源TH-SC01细胞(江苏拓弘康恒医药)",
"lang": "CN"
},
{
"name": "Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical)",
"lang": "EN"
}
]
] | null |
NCT04508660 | [
{
"id_field": "org_study_id",
"id_value": [
"CGB-400-001b"
]
}
] | https://clinicaltrials.gov/study/NCT04508660 | CGB-400 for the Reduction of Facial Redness | Open-label multicenter study using CGB-400 Gel (cosmetic) to reduce facial redness | Effectiveness of CGB-400 (Cosmetic) for the Reduction of Facial Redness | [
{
"description": "BID application",
"name": "CGB-400",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Topical application twice daily for 4 weeks",
"design_group_title": "Subjects with facial redness",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descripti... | [
"Rosacea"
] | [
"CAGE Bio, Inc."
] | [
"ethica Clinical Research Inc."
] | [
[
{
"name": "CGB-400",
"lang": "EN"
}
]
] | null |
NCT04928508 | [
{
"id_field": "org_study_id",
"id_value": [
"OU-SCC-OKGyn1"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01CA196200"
]
},
{
"id_field": "acronym",
"id_value": [
"Okgyn1"
]
},
{
"id_field": "secondar... | https://clinicaltrials.gov/study/NCT04928508 | Advanced or Recurrent Solid Tumors Treated With SHetA2 | The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors. | Phase 1 Trial of OK-1 (SHetA2) in Patients With Advanced or Recurrent Solid Tumors | [
{
"description": "OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:<br/>5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg",
"name": "OK-1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"NSC 726189"
],
"single_or_multi": "single_drug",
"type":... | [
{
"design_group_description": "OK-1 (oral, BID) within a 21-days cycle",
"design_group_title": "OK-1 capsule",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "OK-1 orally in... | [
"Solid Tumor, Adult"
] | [
"University of Oklahoma"
] | [
"National Cancer Institute"
] | [
[
{
"name": "SHetA2",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Okgyn1"
}
] |
NCT02906995 | [
{
"id_field": "org_study_id",
"id_value": [
"16-07-239"
]
}
] | https://clinicaltrials.gov/study/NCT02906995 | Pharmacokinetics of Nicotine Sublingual Tablets Versus Nicorette Lozenge in Healthy Smokers | The purpose of the study is to compare two different dosage forms from which nicotine is released and absorbed into the bloodstream. | An Open-Label Pseudorandomized, Two Way Crossover Comparison of the Single-Dose Pharmacokinetics of Nicotine 4 mg Sublingual Tablets Versus Nicorette Lozenge 4 mg in Healthy Smokers Under Fasted Conditions | [
{
"description": "* One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.<br/>* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed a... | [
{
"design_group_description": "The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.",
"design_group_title": "Sublingual tablet 4 mg",
"design_group_type": "Experimental",
... | [
"Tobacco Use Disorder",
"Cigarette Smoking"
] | [
"Friends Research Institute, Inc."
] | [
"Rose Research Center LLC"
] | [
[
{
"name": "尼古丁",
"lang": "CN"
},
{
"name": "Nicotine",
"lang": "EN"
}
]
] | null |
NCT04375631 | [
{
"id_field": "org_study_id",
"id_value": [
"RG1006914"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2020-02616"
]
},
{
"id_domain": "Fred Hutch/University of Wa... | https://clinicaltrials.gov/study/NCT04375631 | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy reduced-intensity conditioning regimen before stem cell transplant in treating patients with acut... | CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study | [
{
"description": "Given IV",
"name": "Cladribine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2-CdA",
"2CDA",
"CdA",
"Cladribina",
"Leustat",
"Leustatin",
"Leustatine",
"RWJ-26251"
],
"type": "Drug"
},
{
"de... | [
{
"design_group_description": "See detailed description.",
"design_group_title": "Arm I (CLAG-M, TBI, HCT, GVHD prophylaxis)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description":... | [
"Recurrent Acute Myeloid Leukemia",
"Recurrent Chronic Myelomonocytic Leukemia",
"Recurrent Myelodysplastic Syndrome",
"Refractory Acute Myeloid Leukemia",
"Refractory Chronic Myelomonocytic Leukemia",
"Refractory Mixed Phenotype Acute Leukemia",
"Refractory Myelodysplastic Syndrome",
"Refractory Acut... | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "克拉屈滨",
"lang": "CN"
},
{
"name": "Cladribine",
"lang": "EN"
},
{
"name": ... | null |
NCT01052298 | [
{
"id_field": "org_study_id",
"id_value": [
"13013"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2008-006770-14"
]
}
] | https://clinicaltrials.gov/study/NCT01052298 | Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) | Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with mild to moderate COPD (stage I-II according to GOLD Criteria). | Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (GOLD I - II), Following Inhalation of Ciprofloxacin PulmoSphere Inhalation Powder. | [
{
"description": "32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.",
... | [
{
"design_group_title": "Arm 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder... | [
"Disease, Pulmonary"
] | [
"Bayer AG"
] | [
"Novartis AG"
] | [
[
{
"name": "环丙沙星",
"lang": "CN"
},
{
"name": "Ciprofloxacin",
"lang": "EN"
},
{
"name": "シプロフロキサシン",
"lang": "JP"
}
]
] | null |
NCT05806814 | [
{
"id_field": "org_study_id",
"id_value": [
"OU-SCC-EXCITE"
]
},
{
"id_field": "acronym",
"id_value": [
"OU-SCC-EXCITE"
]
},
{
"id_field": "secondary_id",
"id_value": [
"OU-SCC-EXCITE"
]
}
] | https://clinicaltrials.gov/study/NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer | Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). | Pilot Trial to Investigate Immune Response to an Extended Course of Sipuleucel-T Immunotherapy in Patients With Metastatic Castration-resistant Prostate Cancer (OU-SCC-EXCITE) | [
{
"description": "Three doses of Sipuleucel-T, each containing a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, given at week 0, 2, and 12-14.",
"name": "Sipuleucel-T",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"PROVENGE"
],
"type":... | [
{
"design_group_title": "Extended course of Sipuleucel-T treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Three doses of Sipuleucel-T, each containing a minimum of 50... | [
"Metastatic Castration-Resistant Prostate Cancer (mCRPC)"
] | [
"University of Oklahoma"
] | [
"Dendreon Corp."
] | [
[
{
"name": "Sipuleucel-T (Dendreon Corporation)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "OU-SCC-EXCITE"
}
] |
NCT05021887 | [
{
"id_field": "org_study_id",
"id_value": [
"BECRO-RESP-ANASSA-PK100"
]
}
] | https://clinicaltrials.gov/study/NCT05021887 | A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions | Bioequivalence study between two inhaler products of ffluticasone propionate inhalation powder | A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Health... | [
{
"description": "2 inhalations of Test and Reference product in each study period",
"name": "Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Test"
],
"type": "Drug"
},
... | [
{
"design_group_description": "Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals",
"design_group_title": "Test Product",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Asthma",
"Bioequivalence"
] | [
"Respirent Pharmaceuticals Co. Ltd."
] | [
"Becro Ltd."
] | [
[
{
"name": "丙酸氟替卡松",
"lang": "CN"
},
{
"name": "Fluticasone Propionate",
"lang": "EN"
},
{
"name": "フルチカゾンプロピオン酸エステル",
"lang": "JP"
}
]
] | null |
NCT02120807 | [
{
"id_field": "org_study_id",
"id_value": [
"13-063"
]
}
] | https://clinicaltrials.gov/study/NCT02120807 | Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas | The purpose of this study is to test the safety of certolizumab when it is given with the chemotherapy drugs cisplatin and pemetrexed. Cisplatin and pemetrexed are two chemotherapy drugs used in the treatment of lung cancer. The investigators want to find out what effects, good and/or bad, certolizumab has on the patie... | A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas | [
{
"name": "Certolizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "pemetrexed",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third d... | [
"Stage IV Lung Adenocarcinoma"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "培美曲塞二钾",
"lang": "CN"
},
{
"name": "Pemetrexed Dipotassium",
"lang": "EN"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
],
[
... | null |
NCT02460484 | [
{
"id_field": "org_study_id",
"id_value": [
"443002"
]
}
] | https://clinicaltrials.gov/study/NCT02460484 | Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke | Autologous human umbilical cord blood (hUCB) stored at Cord Blood Registry will be given to children who have suffered from a Perinatal Arterial Ischemic Stroke. The aim is to determine if hUCB infusion is safe, if late functional outcome is improved, if hUCB treatment improves physiologic response in the child's SSEP ... | Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal | [
{
"description": "Intravenous infusion",
"name": "Autologous Cord Blood Infusion",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Autologous cord blood infusion",
"design_group_title": "Cord Blood Infusion",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intravenous infu... | [
"Perinatal Arterial Ischemic Stroke"
] | [
"AdventHealth Waterman"
] | [
"CBR Systems, Inc."
] | [
[
{
"name": "Autologous Human Umbilical Cord Blood(AdventHealth)",
"lang": "EN"
}
]
] | null |
NCT02459613 | [
{
"id_field": "org_study_id",
"id_value": [
"C13-38"
]
},
{
"id_field": "acronym",
"id_value": [
"AnnIE"
]
}
] | https://clinicaltrials.gov/study/NCT02459613 | Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis | Intraluminal thrombi adherent to cardiac valves or atria share a common pathophysiology involving the aggregation of activated platelets with phosphatidylserine (PS) expression on the outer layer of the thrombus. They also share common complications, i.e. damages to the underlying myocardium and embolic risk related to... | Evaluation de la rhAnnexine V-128 radiomarquée Dans le Diagnostic de l'Endocardite Infectieuse, du Thrombus Atrial et de Leurs Complications Emboliques associées | [
{
"name": "99mTc-Annexin V-128 SPECT",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "99mTc Annexin V-128 SPECT",
"design_group_title": "Imaging",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "99mTc-Annexin V-128 SPECT",
"int... | [
"Endocarditis",
"Thrombosis"
] | [
"Institut National de la Santé et de la Recherche Médicale"
] | [
"Advanced Accelerator Applications SA"
] | [
[
{
"name": "Tc-99m-annexin V-128",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "d288e2a8e4d08ae2a5304355aa883558",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Phase I/II study of 99m Tc-Annexin A5-128"
},
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
... |
NCT03732703 | [
{
"id_field": "org_study_id",
"id_value": [
"MyDRUG (MMRC-085)"
]
},
{
"id_field": "acronym",
"id_value": [
"MyDRUG"
]
}
] | https://clinicaltrials.gov/study/NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS,... | Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen) | [
{
"description": "Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.",
"name": "Abemaciclib, dexamethasone, ixazomib, pomalidomide",
"normalized... | [
{
"design_group_description": "Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)",
"design_group_title": "Sub-Protocol A1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf... | [
"Relapsed Refractory Multiple Myeloma"
] | [
"Multiple Myeloma Research Consortium"
] | [
"Genentech, Inc.",
"Takeda Pharmaceutical Co., Ltd.",
"Janssen LP",
"Karyopharm Therapeutics, Inc.",
"GSK Plc",
"Celgene Corp.",
"Eli Lilly & Co.",
"AbbVie, Inc."
] | [
[
{
"name": "可美替尼",
"lang": "CN"
},
{
"name": "Cobimetinib Fumarate",
"lang": "EN"
}
],
[
{
"name": "甲磺酸恩西地平",
"lang": "CN"
},
{
"name": "Enasidenib Mesylate",
"lang": "EN"
}
],
[
{
"name": "枸橼酸伊沙佐米",
"lang": "CN... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "220545253488e5dda855a3e5e2824544",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8e5802522322a99e8aedaaa8e2284535",
"s... |
NCT03183206 | [
{
"id_field": "org_study_id",
"id_value": [
"Gd T cell and Breast Ca"
]
}
] | https://clinicaltrials.gov/study/NCT03183206 | Safety and Efficiency of γδ T Cell Against Breast Cancer | In this study, effects of γδT cells on human Breast Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated. | γδ T Cell Immunotherapy for Treatment of Breast Cancer | [
{
"description": "surgery will be used in local tumor",
"name": "Cryosurgery , IRE surgery ,surgery",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"type": "Procedure"
},
{
"description": "γδ T cells will be used against",
"name": "γδ T cells",
"normalized_type": "30faef638a... | [
{
"design_group_description": "In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor",
"design_group_title": "Group A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"in... | [
"Breast Cancer"
] | [
null
] | [
"Jinan University"
] | [
[
{
"name": "γδ T Cell(Fuda Cancer Hospital)",
"lang": "EN"
}
]
] | null |
NCT00682929 | [
{
"id_field": "org_study_id",
"id_value": [
"251429"
]
},
{
"id_domain": "MS Society",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"MS Society Award # RG 3781-A-1"
]
}
] | https://clinicaltrials.gov/study/NCT00682929 | Cannabis for Spasticity in Multiple Sclerosis | The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary progressive multiple sc... | Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study | [
{
"description": "Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.",
"name": "Inhaled Cannabis",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Cannabis"
],
"type": "Drug"
},
{
"description": "Participants will be inst... | [
{
"design_group_description": "Inhaled cannabis is compared to oral placebo.",
"design_group_title": "1) Inhaled Cannabis",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description... | [
"Multiple Sclerosis"
] | [
"University of California, Davis"
] | [
"The National Multiple Sclerosis Society"
] | [
[
{
"name": "屈大麻酚",
"lang": "CN"
},
{
"name": "Dronabinol",
"lang": "EN"
}
]
] | null |
NCT04262427 | [
{
"id_field": "org_study_id",
"id_value": [
"CFTSp148"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-004314-17"
]
},
{
"id_field": "acronym",
"id_value": [
"CAPER"
]
}
] | https://clinicaltrials.gov/study/NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma | This is an open label investigator initiated Phase Ib study of combination pembrolizumab (Keytruda), 200mg IV 3 weekly (Q3W) with 50mg oral cyclophosphamide daily (OD) in metastatic renal cell carcinoma patients. 21 patients will be recruited within the United Kingdom (UK) will to examine the efficacy of the combinatio... | The CAPER Study: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (RCC) (CAPER Trial) | [
{
"description": "cytotoxic chemotherapy",
"name": "Cyclophosphamide 50mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"cyclophosphamide monohydrate"
],
"type": "Drug"
},
{
"description": "potent humanized immunoglobulin (Ig) G4 monoclonal antibody (... | [
{
"design_group_description": "Cyclophosphamide 50mg PO OD for 3 weeks as monotherapy followed by cyclophosphamide 50mg PO OD with pembrolizumab 200mg IV every 3 weeks",
"design_group_title": "Single Group Assignment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561... | [
"Metastatic Renal Cell Carcinoma"
] | [
"The Christie Pathology Partnership LLP"
] | [
"The University of Manchester",
"Merck Sharp & Dohme Corp.",
"The University of Liverpool"
] | [
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CAPER"
}
] |
NCT01543659 | [
{
"id_field": "org_study_id",
"id_value": [
"11-126"
]
},
{
"id_field": "secondary_id",
"id_value": [
"11-126"
]
}
] | https://clinicaltrials.gov/study/NCT01543659 | Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer | The purpose of this study is to define the safety and accuracy of 89Zr-DFO-huJ591 PET scans. By improving our ability to find cancer cells, the investigators hope to be able to improve treatment for patients in the future.<br/>The study doctors want to determine whether a new kind of scan, called a 89Zr-DFO-huJ591 PET ... | A Phase I/II Study of Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer | [
{
"description": "The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (... | [
{
"design_group_description": "Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan u... | [
"Prostate Cancer"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Weill Medical College of Cornell University",
"The Broad Institute, Inc."
] | [
[
{
"name": "89Zr-DFO-huJ591",
"lang": "EN"
}
]
] | null |
NCT05326035 | [
{
"id_field": "org_study_id",
"id_value": [
"JS112-001-I"
]
}
] | https://clinicaltrials.gov/study/NCT05326035 | A Study of WJ05129 in Advanced Malignant Solid Tumors | This study was an open, multicenter Phase I/II clinical study of WJ05129 in patients with locally advanced or metastatic malignant solid tumors in China, which was divided into three stages: Single-dose escalation,Combined dose extension and efficacy extension. The study included screening, treatment and follow-up peri... | A Phase I/II Clinical Study of WJ05129 Tablets in Patients With Locally Advanced or Metastatic Malignant Solid Tumors | [
{
"description": "Twice daily (except for single dose), 12 hours apart, fixed time is recommended",
"name": "WJ05129",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "80mg/m2 (The maximum dose is 80mg/m2 , and the dose can be adjusted according to t... | [
{
"design_group_title": "WJ05129 tablets",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Twice daily (except for single dose), 12 hours apart, fixed time is recommended",
... | [
"Locally Advanced or Metastatic Malignant Solid Tumors"
] | [
"Suzhou Junjing BioSciences Co., Ltd."
] | [
"Parsley Health, Inc."
] | [
[
{
"name": "WJ-05129",
"lang": "EN"
}
],
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル",
"lang": "JP"
}
]
] | null |
NCT03645980 | [
{
"id_field": "org_study_id",
"id_value": [
"Dial-1"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2017-002468-41"
]
},
{
"id_domain": "Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V (AIO)",
... | https://clinicaltrials.gov/study/NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | This clinical trial is a prospective, open label, single arm oncological phase I/II trial in patients with hepatocellular carcinoma and WNT signaling alterations. The trial consists of two parts: Part A is a phase I study investigating the safety of DKN-01 administered as mono- as well as combination therapy with soraf... | A Phase I/II Multicenter, Open-label Study of DKN-01 to Investigate the Anti-tumor Activity and Safety of DKN-01 in Patients With Hepatocellular Carcinoma and WNT Signaling Alterations | [
{
"description": "DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.",
"name": "DKN-01 300 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "DKN-01... | [
{
"design_group_description": "Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose... | [
"Hepatocellular Carcinoma"
] | [
"The Johannes Gutenberg University of Mainz"
] | [
"Cypherpunk Technologies, Inc."
] | [
[
{
"name": "Sirexatamab",
"lang": "EN"
}
],
[
{
"name": "甲苯磺酸索拉非尼",
"lang": "CN"
},
{
"name": "Sorafenib Tosylate",
"lang": "EN"
},
{
"name": "ソラフェニブトシル酸塩",
"lang": "JP"
}
]
] | null |
NCT03883581 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB201802938"
]
},
{
"id_domain": "UF OnCore",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"OCR20392"
]
}
] | https://clinicaltrials.gov/study/NCT03883581 | Impact of Nuedexta on Bulbar Physiology and Function in ALS | Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and anecdotal reports of improvements in speech, salivation or swallowing have been reported. However, no prospective study has been conducted to comprehensively examine and determine the physiologic impact of Nuedexta on both speech and ... | Impact of Nuedexta on Bulbar Physiology and Function in ALS | [
{
"description": "All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. P... | [
{
"design_group_description": "Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 d... | [
"Amyotrophic Lateral Sclerosis"
] | [
"University of Florida"
] | [
"The Amyotrophic Lateral Sclerosis Association",
"Holy Cross Hospital"
] | [
[
{
"name": "氢溴酸右美沙芬/硫酸奎尼丁",
"lang": "CN"
},
{
"name": "Dextromethorphan Hydrobromide/Quinidine Sulfate",
"lang": "EN"
}
]
] | null |
NCT03797092 | [
{
"id_field": "org_study_id",
"id_value": [
"SCIENCE II - Pilot"
]
}
] | https://clinicaltrials.gov/study/NCT03797092 | Stem Cell Therapy in Non-IschEmic Non-treatable Dilated CardiomyopathiEs II: a Pilot Study | The overall aim of the project is to test the feasibility and safety of allogeneic adipose-derived stromal cells (CSCC_ASC) investigational medicinal product, to improve myocardial function in patients with non-ischemic dilated cardiomyopathies (NIDCM) and heart failure. | Stem Cell Therapy in Non-IschEmic Non-treatable Dilated CardiomyopathiEs II: a Pilot Study | [
{
"description": "Active group",
"name": "Allogeneic adipose-derived stromal cells (CSCC_ASC)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Investigational medicinal product"
],
"type": "Biological"
},
{
"description": "No treatment",
"name": "Co... | [
{
"design_group_description": "Allogeneic adipose-derived stromal cells (CSCC_ASC)",
"design_group_title": "Active",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "No ... | [
"Non-ischemic Dilated Cardiomyopathy"
] | [
"Rigshospitalet"
] | [
"UMC Ljubljana"
] | [
[
{
"name": "Adipose-derived MesenchymAl Stem Cells(Rigshospitalet)",
"lang": "EN"
}
]
] | null |
NCT02980341 | [
{
"id_field": "org_study_id",
"id_value": [
"U31402-A-J101"
]
},
{
"id_domain": "JapicCTI",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"JapicCTI-163401"
]
}
] | https://clinicaltrials.gov/study/NCT02980341 | Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer | This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer.<br/>The number of patients and treatmen... | Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer | [
{
"description": "U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)",
"name": "Patritumab Deruxtecan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"U3-1402"
... | [
{
"design_group_description": "Participants receive U3-1402 from 1.6 mg/kg to 8.0 mg/kg, administered via intravenous (IV) solution at 3-week intervals.",
"design_group_title": "Dose Escalation Part",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf... | [
"Metastatic Breast Cancer"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
"Merck Sharp & Dohme LLC",
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "德帕瑞妥单抗",
"lang": "CN"
},
{
"name": "Patritumab Deruxtecan",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "5a4855552523ea0824e425285a2e50a4",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Phase 1/2 study"
},
{
"identifier_source": [
{
"code": "2882025e4e0aa23a84e9e3a03a4ed550",
"source": "CT_... |
NCT04818281 | [
{
"id_field": "org_study_id",
"id_value": [
"VLP-58-1023-Al-K3"
]
},
{
"id_field": "acronym",
"id_value": [
"COVID-19"
]
}
] | https://clinicaltrials.gov/study/NCT04818281 | Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults | This is a VLP SARS-CoV-2 vaccine study of a vaccine developed in Turkey and manufactured according to Good Manufacturing Practices (GMP) requirements. Preclinical toxicology studies on experimental animals are to be concluded. The purpose of this Phase I study is to examine the safety, tolerability, and immunogenicity ... | Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages. | [
{
"description": "VLP adjuvanted vaccine",
"name": "SARS-CoV-2 VLP Vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "0.9% NaCl",
"name": "Placebo",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"... | [
{
"design_group_description": "12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)",
"design_group_title": "Low-Dose Group (Group A)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Covid19"
] | [
"Türkiye Bilimsel ve Teknolojik Arastirma Kurumu"
] | [
"Türkiye Bilimsel ve Teknolojik Arastirma Kurumu",
"Nobelpharma Co., Ltd.",
"Monitor Medikal Arastirma Ve Danismanlik Ticaret Ltd. Sirketi"
] | [
[
{
"name": "SARS-CoV-2 VLP Vaccine(Nobel Pharmaceuticals)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COVID-19"
}
] |
NCT00521248 | [
{
"id_field": "org_study_id",
"id_value": [
"R21DA018207-01"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21DA018207-01"
]
},
{
"id_domain": "NIDA",
"id_field": "secondary_id",
"id_type": "Other Identifier",
... | https://clinicaltrials.gov/study/NCT00521248 | Buprenorphine for the Treatment of Neonatal Abstinence Syndrome | Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not been used for Neonatal Abstinence Syndrome. This tr... | Buprenorphine for the Treatment of Neonatal Abstinence Syndrome | [
{
"description": "sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms",
"name": "buprenorphine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Buprenex (buprenorphine)"
],
"type": "Drug"
},
{
"description": "... | [
{
"design_group_description": "Oral morphine solution",
"design_group_title": "Oral morphine solution",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "0.4 mg/kg/day mo... | [
"Neonatal Abstinence Syndrome"
] | [
"Thomas Jefferson University"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine Hydrochloride",
"lang": "EN"
},
{
"name": "ブプレノルフィン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT03154775 | [
{
"id_field": "org_study_id",
"id_value": [
"CBMG-C2017003"
]
}
] | https://clinicaltrials.gov/study/NCT03154775 | Study of Safety and Efficacy of C-CAR011 in B-NHL Patients | This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). | Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | [
{
"description": "Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg",
"name": "C-CAR011",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Anti-CD19 Chimeric Antigen Receptor T ... | [
{
"design_group_description": "Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene",
"design_group_title": "C-CAR011",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interve... | [
"Refractory or Relapsed Non-Hodgkin Lymphoma"
] | [
"Shanghai Cellular Biopharmaceutical Group Ltd."
] | [
"Shanghai Tongji Hospital"
] | [
[
{
"name": "CBM.CD19嵌合抗原受体T细胞注射液(Chinese People's Liberation Army General Hospital)",
"lang": "CN"
},
{
"name": "C-CAR011",
"lang": "EN"
}
]
] | null |
NCT04476966 | [
{
"id_field": "org_study_id",
"id_value": [
"GRC/1/19/828"
]
}
] | https://clinicaltrials.gov/study/NCT04476966 | Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan) | An open label randomized, single dose, three way three sequence two treatment partial replicate crossover study to determine the bioequivalence of Mirabegron from Bladogra 50 mg Extended Release film coated tablets (Man by Multi-Apex for pharmaceutical Industries -S.A.E for Apex pharma company, Egypt) and Myrbetriq 50 ... | An Open Label Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study to Determine the Bioequivalence of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Mar... | [
{
"description": "1 tablet contains 25 mg Mirabegron",
"name": "Bladogra",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Myrbetriq"
],
"type": "Drug"
},
{
"description": "1 tablet contains 25 mg Mirabegron",
"name": "Myrbetriq (first dosing)",
... | [
{
"design_group_description": "Test drug (Bladogra)1 extended release tablet contains 25 mg Mirabegron",
"design_group_title": "T test",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_des... | [
"Healthy"
] | [
"Genuine Research Center - Grc"
] | [
"Multi/Apex Pharma for Pharmaceuticals Industries"
] | [
[
{
"name": "米拉贝隆",
"lang": "CN"
},
{
"name": "Mirabegron",
"lang": "EN"
},
{
"name": "ミラベグロン",
"lang": "JP"
}
]
] | null |
NCT04903080 | [
{
"id_field": "org_study_id",
"id_value": [
"PBTC-059"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"UM1CA081457"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type"... | https://clinicaltrials.gov/study/NCT04903080 | HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma | This is a Phase I study to evaluate the safety profile of a type of immune therapy called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (... | Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma | [
{
"description": "HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.",
"name": "HER2 Specific CAR T Cell",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progressi... | [
"Ependymoma"
] | [
"The Children's Oncology Group Foundation, Inc."
] | [
"National Cancer Institute",
"Baylor College of Medicine",
"Texas Children's Cancer & Hematology Centers"
] | [
[
{
"name": "Autologous-HER2-specific-T-cells(Baylor College of Medicine)",
"lang": "EN"
}
]
] | null |
NCT07158905 | [
{
"id_field": "org_study_id",
"id_value": [
"IMM-AV1980R-102"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01AG092949-01"
]
},
{
"id_field": "acronym",
"id_value": [
"TAURUS-1980"
]
}
] | https://clinicaltrials.gov/study/NCT07158905 | AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) | This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adul... | A Phase I, Randomized, Double-Blind Study to Evaluate the Safety and Tolerability of AV-1980R in Participants With Preclinical Alzheimer's Disease | [
{
"description": "MultiTEP-based investigational tau vaccine formulated with the adjuvant. The vaccine is designed to elicit anti-tau antibodies in participants with preclinical Alzheimer's disease.",
"name": "AV-1980R 20 µg",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biologica... | [
{
"design_group_description": "Participants receive 20 µg AV-1980R intramuscularly at Weeks 0, 4, 12, and 36.",
"design_group_title": "AV-1980R 20 µg Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Alzheimer Disease",
"Preclinical Alzheimer's Disease"
] | [
"The Institute for Molecular Medicine"
] | [
"National Institute on Aging"
] | [
[
{
"name": "AV-1980R",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TAURUS-1980"
}
] |
NCT00921661 | [
{
"id_field": "org_study_id",
"id_value": [
"TCD10794"
]
}
] | https://clinicaltrials.gov/study/NCT00921661 | Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer | The primary objective is to determine the dose of aflibercept to be further studied in combination with irinotecan/5-fluorouracil/isovorin (FOLFIRI) in Japanese patients with metastatic colorectal cancer.<br/>Secondary objectives of this study are to assess the safety profile of aflibercept, to determine the pharmacoki... | A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer | [
{
"description": "IV infusion",
"name": "AVE0005 (aflibercept)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "AVE0005 (aflibercept)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "IV infusion",
"intervention_name": "AVE0005 (aflibercept)",
"int... | [
"Colorectal Neoplasms",
"Neoplasm Metastasis"
] | [
"Sanofi"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
[
{
"name": "阿柏西普",
"lang": "CN"
},
{
"name": "Aflibercept",
"lang": "EN"
},
{
"name": "アフリベルセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT00529386 | [
{
"id_field": "org_study_id",
"id_value": [
"BOTOX-CP"
]
}
] | https://clinicaltrials.gov/study/NCT00529386 | Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) | The objective of this study is to evaluate the safety and efficacy of intraprostatic injection of Botox for the treatment of men diagnosed with chronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS). | A Prospective Pilot Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome | [
{
"description": "300 units",
"name": "Botox",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Botulinem toxin"
],
"type": "Drug"
}
] | [
{
"design_group_description": "300 IU botox",
"design_group_title": "Botox",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "300 units",
"intervention_name": "Botox"... | [
"Prostatitis",
"Chronic Pain Syndrome"
] | [
"Queen's University"
] | [
"Allergan UC"
] | [
[
{
"name": "A型肉毒毒素",
"lang": "CN"
},
{
"name": "Onabotulinumtoxin A",
"lang": "EN"
},
{
"name": "A 型ボツリヌス毒素",
"lang": "JP"
}
]
] | null |
NCT02834611 | [
{
"id_field": "org_study_id",
"id_value": [
"KNAN1001"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R44CA195793"
]
}
] | https://clinicaltrials.gov/study/NCT02834611 | Ceramide NanoLiposome in Patients With Advanced Solid Tumors | This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors. | Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors | [
{
"description": "Intravenous administration of Ceramide NanoLiposome",
"name": "Ceramide NanoLiposome",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Dose escalation of Ceramide NanoLiposome",
"design_group_title": "Ceramide NanoLiposome",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intr... | [
"Cancer",
"Carcinoma",
"Solid Tumors",
"Tumor"
] | [
"PendreaBio Inc."
] | [
"National Cancer Institute",
"National Institutes of Health"
] | [
[
{
"name": "Ceramide NanoLiposome(Keystone Nano, Inc.)",
"lang": "EN"
}
]
] | null |
NCT04169321 | [
{
"id_field": "org_study_id",
"id_value": [
"2019-hGZP-101.12"
]
}
] | https://clinicaltrials.gov/study/NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | First in Human Safety of [68Ga]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy | First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy | [
{
"description": "[68Ga]-NOTA-hGZP is a PET imaging agent.",
"name": "Single Arm",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CSB-111",
"[68Ga]-NOTA-hGZP"
],
"type": "Drug"
}
] | [
{
"design_group_description": "All participants will receive a mass dose of 40 μg or less of [68Ga]-NOTA-hGZP (radioactivity dose of 3 mCi to 8 mCi) and have a PET and CT scan.",
"design_group_title": "Single Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b... | [
"Solid Tumor, Unspecified, Adult",
"Lymphoma"
] | [
"Cytosite Biopharma, Inc."
] | [
"The General Hospital Corp.",
"Chang Gung Memorial Hospital",
"The University of Alabama at Birmingham"
] | [
[
{
"name": "Gallium-68 NOTA hGZP",
"lang": "EN"
}
]
] | null |
NCT01026558 | [
{
"id_field": "org_study_id",
"id_value": [
"CR014185"
]
},
{
"id_domain": "Basilea (Internal Reference)",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"CSI-1008"
]
}
] | https://clinicaltrials.gov/study/NCT01026558 | A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients | The primary objective of this study is to compare the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole in morbidly obese patients and non-obese patients. The secondary objectives are to assess the pharmacodyn... | Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients | [
{
"description": "Ceftobiprole, 500 mg as single iv infusion over 2 hours",
"name": "Ceftobiprole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Ceftobiprole 500 mg single-dose over 2 hours.",
"design_group_title": "Ceftobiprole (not morbidly obese subjects)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"i... | [
"Obesity",
"Staphylococcal Skin Infections",
"Streptococcal Infections"
] | [
"Basilea Pharmaceutica AG"
] | [
"Johnson & Johnson Pharmaceutical Research & Development LLC"
] | [
[
{
"name": "头孢比罗酯钠",
"lang": "CN"
},
{
"name": "Ceftobiprole Medocaril Sodium",
"lang": "EN"
}
]
] | null |
NCT03216954 | [
{
"id_field": "org_study_id",
"id_value": [
"BED IN 34"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21AA026129"
]
}
] | https://clinicaltrials.gov/study/NCT03216954 | Influence of n-Acetylcysteine Maintenance on Alcohol Effects | This study will evaluate the behavioral effects of alcohol during placebo and n-acetylcysteine maintenance using sophisticated human laboratory methods. | A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder | [
{
"description": "During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.",
"name": "Alcohol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Subjects will receive placebo capsules",
"name": "Plac... | [
{
"design_group_description": "Subjects will receive oral placebo capsules two times daily.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_descrip... | [
"Alcohol Use Disorder"
] | [
"University of Kentucky"
] | [
"National Institute on Alcohol Abuse & Alcoholism"
] | [
[
{
"name": "乙酰半胱氨酸",
"lang": "CN"
},
{
"name": "Acetylcysteine",
"lang": "EN"
},
{
"name": "アセチルシステイン",
"lang": "JP"
}
]
] | null |
NCT01864083 | [
{
"id_field": "org_study_id",
"id_value": [
"11-177"
]
}
] | https://clinicaltrials.gov/study/NCT01864083 | FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients | This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or PEM can accurately measure your response to chemotherapy. | FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients | [
{
"name": "Positron Emission Tomography (PET)",
"normalized_type": "a49da0f516744e0f8a08ffdea4946e99",
"type": "Procedure"
},
{
"name": "Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
... | [
{
"design_group_description": "Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.",
"design_group_title": "Local staging patients",
"design_group_type": "Experimental",
"design_group_type_normal... | [
"Breast Cancer"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"GE Healthcare Holdings, Inc."
] | [
[
{
"name": "[18F]氟氨基丁酸",
"lang": "CN"
},
{
"name": "Fluciclovine 18F",
"lang": "EN"
},
{
"name": "フルシクロビン（18F）",
"lang": "JP"
}
]
] | null |
NCT05368506 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00022229"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2022-03599"
]
},
{
"id_domain": "OHSU Knight Cancer Inst... | https://clinicaltrials.gov/study/NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | This early phase I trial tests the safety and side effects of ZN-c3 in treating patients with triple-negative breast cancer or ovarian cancer that have spread to other parts of the body (metastatic or advanced). ZN-c3 is an enzyme inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed... | An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors | [
{
"description": "Given PO",
"name": "Wee1 Inhibitor ZN-c3",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ZN c3",
"ZN-c3",
"ZNc3"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients receive Wee1 inhibitor ZN-c3 PO QD on days 1-21. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.",
"design_group_title": "Treatment (wee1 inhibitor ZN-c3)",
"design_group_type": "Experimental",
... | [
"Advanced Fallopian Tube Carcinoma",
"Advanced Ovarian Carcinoma",
"Advanced Primary Peritoneal Carcinoma",
"Anatomic Stage IV Breast Cancer AJCC v8",
"Metastatic Triple-Negative Breast Carcinoma",
"Stage III Fallopian Tube Cancer AJCC v8",
"Stage III Ovarian Cancer AJCC v8",
"Stage III Primary Perito... | [
"OHSU Knight Cancer Institute"
] | [
"Oregon Health & Science University"
] | [
[
{
"name": "Azenosertib",
"lang": "EN"
}
]
] | null |
NCT07349160 | [
{
"id_field": "org_study_id",
"id_value": [
"LM-META10-TIL-12"
]
},
{
"id_field": "secondary_id",
"id_value": [
"LM-META10-TIL-12"
]
}
] | https://clinicaltrials.gov/study/NCT07349160 | Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors | Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | [
{
"description": "Each subject receive metabolically armed TIL cells by intravenous infusion.",
"name": "Metabolically Armed TIL cells.",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Meta10-TIL"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients will receive a nonmyeloablative lymphodepletionl chemotherapy with cyclophosphamide and fludarabine before TIL cells infusion. Meta10-TIL cells will be infused on day 0.",
"design_group_title": "Administration of Metabolically Armed tumor-infiltrating lymphocytes (Met... | [
"Advanced Solid Tumors"
] | [
"Cancer Hospital Chinese Academy of Medical Sciences"
] | [
"Leman Biotech Co., Ltd."
] | [
[
{
"name": "Metabolically Armed Tumor-lnfiltrating Lymphocytes(Leman Biotech)",
"lang": "EN"
}
]
] | null |
NCT04116164 | [
{
"id_field": "org_study_id",
"id_value": [
"GID5490"
]
}
] | https://clinicaltrials.gov/study/NCT04116164 | Safety and Targeting of Anti-hk2 Antibody in mCRPC | This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC.<br/>This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In) radiolabeled h11B6 in subjects ... | A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects With Metastatic Castration-resistant Prostate Cancer. | [
{
"description": "4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.",
"name": "111In-DOTA-h11B6",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Three sub-cohorts in cohort 1 will receive one slow bolus IV injection of 2 mg 111In-DOTA-h11B6 with 0, 8 and 18 mg unlabeled h11B6 respectively.<br/>In cohort 2, up to 6 patients will receive a slow bolus IV injection of 2 mg 111In-DOTA_h11B6 with any unlabeled h11B6 as determine... | [
"Castration-Resistant Prostatic Cancer",
"Metastatic Disease"
] | [
"SpectronRx"
] | [
"Invicro LLC",
"Tomopath Inc.",
"Janssen Research & Development LLC"
] | [
[
{
"name": "111In-DOTA-h11B6",
"lang": "EN"
}
]
] | null |
NCT05683964 | [
{
"id_field": "org_study_id",
"id_value": [
"22-441"
]
},
{
"id_field": "secondary_id",
"id_value": [
"22-441"
]
}
] | https://clinicaltrials.gov/study/NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | The goal of this research study is to determine whether hormonal therapies used early in the course of prostate cancer could increase the amount of Prostate-Specific Membrane Antigen (PSMA) as detected by PET/CT scans for participants with recurrent prostate cancer. This study will measure PSMA levels using standard PE... | Understanding the Interaction Between Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | [
{
"description": "per standard care",
"name": "Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Per standard care",
"name": "Prostate-Specific Membrane Antigen (PSMA) PET/CT... | [
{
"design_group_description": "* Participants will receive pre-determined doses of apalutamide, darolutamide, or enzalutamide per standard care.<br/>* Participants will undergo Prostate-Specific Membrane Antigen (PSMA) PET/CT scans at weeks 1 and 4.",
"design_group_title": "Androgen Receptor Antagonist Mono... | [
"Prostate Adenocarcinoma",
"Prostate Cancer",
"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
] | [
"Beth Israel Deaconess Medical Center, Inc."
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
],
[
{
"name": "阿帕他胺",
"lang": "CN"
},
{
"name": "Apalutamide",
"lang": "EN"
},
{
"name"... | null |
NCT01764451 | [
{
"id_field": "org_study_id",
"id_value": [
"BVMC 6205"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U54NS065705"
]
}
] | https://clinicaltrials.gov/study/NCT01764451 | Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins | Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. In some patients, CCMs affect the blood brain barrier (BBB). The BBB is the body's separation of blood and its contents in the brain from the brain tissue its... | Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins | [
{
"name": "Simvastatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Zocor"
],
"type": "Drug"
}
] | [
{
"design_group_description": "20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.",
"design_group_title": "Simvastatin",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Cavernous Angioma, Familial",
"Cerebral Cavernous Malformations",
"Cerebral Cavernous Hemangioma"
] | [
"The University of New Mexico"
] | [
"National Institute of Neurological Disorders & Stroke",
"The University of California, San Francisco"
] | [
[
{
"name": "辛伐他汀",
"lang": "CN"
},
{
"name": "Simvastatin",
"lang": "EN"
},
{
"name": "シンバスタチン",
"lang": "JP"
}
]
] | null |
NCT05948683 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB23-0219"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01DA002812-35"
]
},
{
"id_field": "acronym",
"id_value": [
"PEM"
]
}
] | https://clinicaltrials.gov/study/NCT05948683 | Prosocial Effects of MDMA | In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person | Effects of Familiarity on Prosocial Effects of MDMA | [
{
"description": "The stimulant MDMA",
"name": "MDMA",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Dextrose",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participant engages in social interaction with 'familiar' partner under placebo",
"design_group_title": "Familiar partner with placebo",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"MDMA ('Ecstasy')",
"Social Interaction"
] | [
"The University of Chicago"
] | [
"National Institute on Drug Abuse",
"National Institutes of Health"
] | [
[
{
"name": "亚甲二氧甲基苯丙胺",
"lang": "CN"
},
{
"name": "Methylenedioxymetamfetamine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PEM"
}
] |
NCT04645602 | [
{
"id_field": "org_study_id",
"id_value": [
"HIC 2000035849"
]
}
] | https://clinicaltrials.gov/study/NCT04645602 | Merck IIT: RRP Pembro and Lenvatinib | This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP).<br/>The names of the study drugs involved in this study are:<br/>* Pembrolizumab<br/>* Lenvatinib | A Pilot Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patients | [
{
"description": "Pill taken by mouth, once daily.",
"name": "Lenvatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lenvima"
],
"type": "Drug"
},
{
"description": "Intravenous injection through a vein (IV).",
"name": "Pembrolizumab",
"norm... | [
{
"design_group_description": "Participants will take:<br/>Lenvatinib - At a pre-determined dose daily during each 3 week study cycle up to 9 cycles<br/>Pembrolizumab - 200 mg infusion on Day 1 of each 3 week study cycle up to 35 cycles<br/>Participants will be given a drug diary and asked to document informati... | [
"Human Papilloma Virus",
"Recurrent Respiratory Papillomatosis",
"Pulmonary Disease"
] | [
"Yale University"
] | [
"Merck Sharp & Dohme Corp.",
"Eisai, Inc."
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "甲磺酸仑伐替尼",
"lang": "CN"
},
{
"name": "Lenvatinib mesylate",
"lang": "EN"
... | null |
NCT04439721 | [
{
"id_field": "org_study_id",
"id_value": [
"PG-γδT-001"
]
},
{
"id_field": "acronym",
"id_value": [
"γδT"
]
}
] | https://clinicaltrials.gov/study/NCT04439721 | γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse | Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation | Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation | [
{
"description": "γδT",
"name": "γδT Cell infusion agent",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.",
"design_group_title": "γδT",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "γδT",
"int... | [
"Leukemia, B-cell"
] | [
"PersonGen BioTherapeutics (Suzhou) Co., Ltd."
] | [
"The First Affiliated Hospital of Soochow University"
] | [
[
{
"name": "Donor γδT Cell(PersonGen BioTherapeutics)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "γδT"
}
] |
NCT04121494 | [
{
"id_field": "org_study_id",
"id_value": [
"CHADOX"
]
},
{
"id_field": "acronym",
"id_value": [
"TB039"
]
}
] | https://clinicaltrials.gov/study/NCT04121494 | ChAdOx1 85A Aerosol Versus Intramuscular Vaccination in Healthy Adults (TB039) | This is a dose escalating and a paired-placebo design study to describe the safety and immunogenicity profile of candidate TB vaccine ChAdOx1 85A given by aerosol inhaled vaccination versus intramuscular (IM) vaccination in adult healthy volunteers.<br/>It is postulated that the aerosol inhaled route is practical and f... | A Phase I Clinical Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine ChAdOx1 85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Subjects | [
{
"description": "Aerosol administration through the Omron MicroAIR NE-U22 nebuliser",
"name": "ChadOx1 85A - aerosol",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Intramuscular administration",
"name": "ChadOx1 85A - IM",
"normali... | [
{
"design_group_description": "BCG-vaccinated, 1x10^9 vp, aerosol",
"design_group_title": "Group A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Aerosol administration t... | [
"Mycobacterium Tuberculosis, Protection Against",
"Tuberculosis"
] | [
"Centre Hospitalier Universitaire Vaudois"
] | [
"University of Oxford"
] | [
[
{
"name": "ChAdOx1-85A",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TB039"
}
] |
NCT04670055 | [
{
"id_field": "org_study_id",
"id_value": [
"hBCMA-ZhejiangU"
]
}
] | https://clinicaltrials.gov/study/NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma | Clinical Trial for the Safety and Efficacy of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | [
{
"description": "Each subject receive BCMA Targeted CAR T-cells by intravenous infusion",
"name": "BCMA Targeted CAR T-cells",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BCMA Targeted CAR T-cells injection"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels are set for subjects.",
"design_group_title": "Administration of BCMA Targeted CAR T-cells",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3... | [
"Relapse Multiple Myeloma",
"Refractory Multiple Myeloma"
] | [
"Zhejiang University"
] | [
"Shanghai Yake Biotechnology Co., Ltd"
] | [
[
{
"name": "Anti BCMA CART cell therapy(Shanghai YaKe Biotechnology Co Ltd)",
"lang": "EN"
}
]
] | null |
NCT00644137 | [
{
"id_field": "org_study_id",
"id_value": [
"0701002184"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA020752"
]
},
{
"id_domain": "VA",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_va... | https://clinicaltrials.gov/study/NCT00644137 | GABA (Gamma Amino Butyric Acid) Medication for Tobacco | The goal of this study is to examine the effects of a GABA (gamma amino butyric acid)-enhancing medication, pregabalin (300 mg/day), on smoking behavior, tobacco withdrawal and cigarette craving in smokers. We hypothesize that in smokers, pregabalin at 300 mg/day, will be more effective than placebo in decreasing smoki... | Pregabalin Given to Tobacco Users to Study Addiction | [
{
"description": "Help stop smoking",
"name": "pregabalin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"300mg/day for pregabalin with smoking cigarettes"
],
"type": "Drug"
},
{
"description": "help stop smoking with study medication",
"name": "ci... | [
{
"design_group_description": "pregabalin 300mg/day given in conjunction with smoking cigarettes.",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description":... | [
"Nicotine Dependence"
] | [
"Yale University"
] | [
"National Institute on Drug Abuse",
"US Department of Veterans Affairs (District of Columbia)"
] | [
[
{
"name": "普瑞巴林",
"lang": "CN"
},
{
"name": "Pregabalin",
"lang": "EN"
},
{
"name": "プレガバリン",
"lang": "JP"
}
]
] | null |
NCT02520882 | [
{
"id_field": "org_study_id",
"id_value": [
"PUMCHNM11"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"ZIAEB000073"
]
}
] | https://clinicaltrials.gov/study/NCT02520882 | 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas | This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-Aca-BBN(7-14) in glioma patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-Aca-BBN(7-14) will be injected intravenously. Visual and semiquan... | Safety and Diagnostic Performance of 68Gallium-labeled NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas | [
{
"description": "68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans",
"name": "68Ga-NOTA-Aca-BBN",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"68Ga-NOTA-Aca-BBN(7-14)"
],
"type": "Drug"
},
{
"name": "PET/CT",
"normal... | [
{
"design_group_description": "The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.",
"design_group_title": "68Ga-NOTA-Aca-BBN(7-14) PET/CT",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "7... | [
"Glioma"
] | [
"Peking Union Medical College Hospital"
] | [
"National Institute For Biomedical Imaging And Bioengineering (Nibib)"
] | [
[
{
"name": "Gallium-68-NOTA-Aca-BBN(7-14)",
"lang": "EN"
}
]
] | null |
NCT01570283 | [
{
"id_field": "org_study_id",
"id_value": [
"H-29966 ARMS"
]
},
{
"id_field": "acronym",
"id_value": [
"ARMS"
]
}
] | https://clinicaltrials.gov/study/NCT01570283 | ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus | The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant. The donor of the stem cells will be either the subject's brother or sister, or another relative, or a closely matched unrelated donor. The Investigators are... | ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant | [
{
"description": "The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.<br/>Dose Level One: 5x10^6 mCTLs/m2<br/>There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the... | [
{
"design_group_description": "Cohort 1 prophylaxis: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.",
"design_group_title": "Multivirus-specific T cells 5*10^6... | [
"Viral Infection"
] | [
"AlloVir, Inc."
] | [
"Center For Cell & Gene Therapy",
"Baylor College of Medicine",
"The Methodist Hospital Research Institute"
] | [
[
{
"name": "Multivirus-specific cytotoxic T lymphocytes (AlloVir)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "05059859852ad8aa24e88922990e5282",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ARMS"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.